<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00851721</url>
  </required_header>
  <id_info>
    <org_study_id>090701</org_study_id>
    <nct_id>NCT00851721</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor</brief_title>
  <official_title>FEIBA NF: A Prospective, Open-label, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Prophylactic Versus On-Demand Treatment in Subjects With Hemophilia A or B and a High Titer Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study was to determine the efficacy, safety, and health-related quality of
      life benefits with FEIBA NF prophylactic treatment as compared with on-demand treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Annualized Bleeding Episode Rate (ABR) Among Participants Receiving Prophylactic Treatment as Compared to Those Treated On-demand</measure>
    <time_frame>12 months ± 14 days</time_frame>
    <description>Participants were Randomized to Receive 1 of the 2 Following Treatment Regimens:
On-Demand: FEIBA NF dose &amp; dosing interval as prescribed by treating physician
Prophylaxis: 85 ± 15 U/kg of FEIBA NF every other day during 12-month prophylactic period
Annualized rate of bleeding episodes was calculated as:
(Number of bleeding episodes/observed treatment period in days) * 365.25</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized Bleeding Rate by Treatment Regimen, Bleeding Etiology, and Bleed Type</measure>
    <time_frame>12 months ± 14 days</time_frame>
    <description>Spontaneous includes unknown/undermined etiology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in Mean Transformed Annualized Bleeding Rate Between On-Demand and Prophylaxis Treatment Regimens by Bleeding Etiology, and Bleeding Type</measure>
    <time_frame>12 months ± 14 days</time_frame>
    <description>Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the t-test.
The difference in mean transformed ABRs was used to perform statistical tests and generate p-values at a significance level of 5%
Participants were Randomized to Receive 1 of the 2 Following Treatment Regimens:
On-Demand: FEIBA NF dose &amp; dosing interval as prescribed by treating physician
Prophylaxis: 85 ± 15 U/kg of FEIBA NF every other day during 12-month prophylactic period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Bleeding Rate for New Target Joints</measure>
    <time_frame>12 months ± 14 days</time_frame>
    <description>Target joints are ≥4 bleeds/6 months in any one of the following joints: ankles, knees, elbows, and hips; a target joint bleeding episode refers to an individual anatomical location.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in Mean Transformed Annualized Bleeding Rate Between On-Demand and Prophylaxis Treatment Regimens: New Target Joints</measure>
    <time_frame>12 months ± 14 days</time_frame>
    <description>Annualized bleed rates (ABRs) were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using a two-sample, two-sided t-test.
The difference in mean transformed ABRs was used to perform statistical tests and generate p-values at a significance level of 5%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of New Target Joints</measure>
    <time_frame>12 months ± 14 days</time_frame>
    <description>Target Joints are defined as ≥4 bleeds/6 months in any one of the following joints: ankles, knees, elbows and hips</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Objective Clinical Symptoms- Visual Analog Scale (VAS): Pain in Adolescents and Adults (≥12 Years Old)</measure>
    <time_frame>Throughout the study period, 12 months ± 14 days</time_frame>
    <description>Pain caused by a bleeding episode in adolescents and adults (≥12 years old) was measured at pre-infusion (pre-inf) and at 6 ± 0.5 hours (h) and 24 ± 1 h post-infusion (post-inf) (after the last infusion given to treat a bleeding episode) on the VAS pain scale in millimeters from 0 (no pain) to 100 (worst possible pain). For analysis purposes, if short acting analgesics (duration of activity approximately 6 ± 0.5 h) were used, pain was assigned the highest possible score (100). Pain assessment occurred after each infusion related to single bleeding episodes. In case participants required an additional infusion within 24h, pain was assessed 6 ± 0.5 h and 24 ±1 h following the subsequent infusion.
Change in VAS scores at 6 ± 0.5 h and 24 ±1 h post-infusion were also compared relative to pre-infusion VAS scores (ie, (pre-infusion VAS score) - (post-infusion VAS score)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Clinical Symptoms - Visual Analog Scale (VAS): Pain in Pediatrics (&lt;12 Years Old)</measure>
    <time_frame>12 months ± 14 days</time_frame>
    <description>Pain caused by a bleeding episode (BE) in pediatric participants (&lt;12 years old) was measured at pre-infusion (pre-inf) and at 6 ± 0.5 h and 24 ± 1 h post-infusion (post-inf) (after the last infusion given to treat a bleeding episode) using the children's VAS pain scale (a facial expression scale with one end marked as no pain and the opposite end marked as the worst possible pain). For analysis purposes, if short acting analgesics (duration of activity approximately 6 ± 0.5 h) were used, pain was assigned the highest possible score (worst possible pain).
Scores on the children's VAS scale are presented as:
No Pain
Mild Pain
Moderate pain
Severe pain
Very severe pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Clinical Symptoms - Range of Motion (ROM)</measure>
    <time_frame>12 months ± 14 days</time_frame>
    <description>ROM was measured using a goniometer for 3 key joints (ie, ankles, knees, and elbows) at screening, month 6, and termination (end of study visit)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Hemostasis for Treatment of Bleeding Episodes- Overall Efficacy Rating at 6 Hours</measure>
    <time_frame>6 h ± 30 min post-infusion</time_frame>
    <description>Number of rAHF-PFM-treated bleeding episodes with an assessment of hemostasis (4-point ordinal scale):
Excellent: Full pain relief &amp; bleeding cessation within ~6 hours of 1 infusion. Additional infusions may have been given to maintain hemostasis;
Good: Definite pain relief and/or improvement in bleeding within ~6 hours after infusion. Possibly requires &gt;1 infusion for complete resolution;
Fair: Probable or slight relief of pain &amp; slight improvement in bleeding within
~6 hours after infusion. Requires &gt;1 infusion for complete resolution;
None: No improvement or condition worsens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Hemostasis for Treatment of Bleeding Episodes- Overall Efficacy Rating at 24 Hours</measure>
    <time_frame>24 ± 1 h post-infusion</time_frame>
    <description>Number of rAHF-PFM-treated bleeding episodes with an assessment of hemostasis (4-point ordinal scale):
Excellent: Full pain relief &amp; bleeding cessation within ~24 hours of 1 infusion. Additional infusions may have been given to maintain hemostasis;
Good: Definite pain relief and/or improvement in bleeding within ~24 hours after infusion. Possibly requires &gt;1 infusion for complete resolution;
Fair: Probable or slight relief of pain &amp; slight improvement in bleeding within
~24 hours after infusion. Requires &gt;1 infusion for complete resolution;
None: No improvement or condition worsens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Weight Adjusted Dose to Control a Bleeding Episode</measure>
    <time_frame>12 months ± 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Bleeding Episode (BE) Which Required 1, 2, 3, or ≥4 Infusions to Control Bleeding</measure>
    <time_frame>12 months ± 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal Activated Partial Thromboplastin Time (aPTT) Assay Results</measure>
    <time_frame>Screening visit, Month 3, Month 6, Month 9, and Termination visit</time_frame>
    <description>The normal reference range of values for aPTT is 22.8 - 31 seconds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal D-Dimer Assay Results</measure>
    <time_frame>Screening visit, Month 3, Month 6, Month 9, and Termination visit</time_frame>
    <description>The normal reference range of values for D-dimers is &lt;500 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal Fibrinogen Assay Results</measure>
    <time_frame>Screening visit, Month 3, Month 6, Month 9, and Termination visit</time_frame>
    <description>The normal reference range of values for fibrinogen is 200-400 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal Fibrin Degradation Products (FDP) Assay Results</measure>
    <time_frame>Screening visit, Month 3, Month 6, Month 9, and Termination visit</time_frame>
    <description>The normal reference range of values for FDP is 0-5 ug/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal Prothrombin Fragment F 1.2 Assay Results</measure>
    <time_frame>Screening visit, Month 3, Month 6, Month 9, and Termination visit</time_frame>
    <description>The normal reference range of values for prothrombin fragment F 1.2 is 69-229 pmol/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal Prothrombin Time Assay Results</measure>
    <time_frame>Screening visit, Month 3, Month 6, Month 9, and Termination visit</time_frame>
    <description>The normal reference range of values for PT is 9.7-12.3 sec.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal Thrombin-Antithrombin III (TAT) Assay Results</measure>
    <time_frame>Screening visit, Month 3, Month 6, Month 9, and Termination visit</time_frame>
    <description>The normal reference range of values for TAT is 1-4.1 ug/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Serology From Screening Visit and Study Termination Visit: Hepatitis A, Hepatitis B, and Hepatitis C</measure>
    <time_frame>12 months ± 14 days</time_frame>
    <description>Hepatitis A Virus Antibody (HAV Ab)
Hepatitis B Virus Core Antibody (HBcAb)
Hepatitis B Virus Surface Antibody (HBsAb)
Hepatitis B Virus Surface Antigen (HBsAg)
Hepatitis C Virus (HCV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Serology From Screening Visit and Study Termination Visit: HIV-1/2 Antibody (Ab)</measure>
    <time_frame>12 months ± 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Serology From Screening Visit and Study Termination Visit: Parvovirus B19 IgG Antibody [IV]</measure>
    <time_frame>12 months ± 14 days</time_frame>
    <description>Normal range (0 - 0.89 IV); High (&gt; 0.89 IV)
- Parvovirus B19 IgG Antibody [IV] (Parvo IgG Ab)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Serology From Screening Visit and Study Termination Visit: Parvovirus B19 IgM Antibody [IV]</measure>
    <time_frame>12 months ± 14 days</time_frame>
    <description>Normal range (0 - 0.89 IV); High (&gt; 0.89 IV)
- Parvovirus B19 IgM Antibody [IV] (Parvo IgM Ab)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Related Adverse Events (AEs) Per Year</measure>
    <time_frame>12 months ± 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Related Adverse Events (AEs) During or Within 1 Hour of Infusion Per Year</measure>
    <time_frame>12 months ± 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Related Thromboembolic Adverse Events (AEs)</measure>
    <time_frame>12 months ± 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Changes in Inhibitor Titer of Hemophilia A Participants With Shifts in Factor VIII (FVIII) Inhibitor Titer Levels</measure>
    <time_frame>12 months ± 14 days</time_frame>
    <description>Absolute Changes in Inhibitor Titer (or no change in low or high titer status):
Inhibitor Titer went from Low (≤5 BU) to Low (≤5 BU)
Inhibitor Titer went from Low (≤5 BU) to High (&gt;5 BU)
Inhibitor Titer went from High (&gt;5 BU) to Low (≤5 BU)
Inhibitor Titer went from High (&gt;5 BU) to High (&gt;5 BU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Changes in Inhibitor Titer of Hemophilia B Participants With Shifts in Factor IX (FIX) Inhibitor Titer Levels</measure>
    <time_frame>12 months ± 14 days</time_frame>
    <description>Absolute Changes in Inhibitor Titer (or no change in low or high titer status):
Inhibitor Titer went from Low (≤5 BU) to Low (≤5 BU)
Inhibitor Titer went from Low (≤5 BU) to High (&gt;5 BU)
Inhibitor Titer went from High (&gt;5 BU) to Low (≤5 BU)
Inhibitor Titer went from High (&gt;5 BU) to High (&gt;5 BU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacoeconomics: Annual Days Lost Due to Bleeding (Work or School)</measure>
    <time_frame>12 months ± 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacoeconomics: Annual Number of Hospitalizations for Bleeding</measure>
    <time_frame>12 months ± 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacoeconomics: Annual Number of Hospitalizations for Indwelling Line</measure>
    <time_frame>12 months ± 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacoeconomics: Annual Number of Emergency Room Visits</measure>
    <time_frame>12 months ± 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacoeconomics: Annual Number of Physician's Office Visits</measure>
    <time_frame>12 months ± 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacoeconomics: Annual Total Length of Hospitalization for Bleeding</measure>
    <time_frame>12 months ± 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacoeconomics: Annual Total Length of Hospitalization for Indwelling Line</measure>
    <time_frame>12 months ± 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacoeconomics: Annual Total Number of Days Lost (Work or School)</measure>
    <time_frame>12 months ± 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HRQoL): EuroQoL (Quality of Life)-5 Dimensions (EQ-5D) Index Scores</measure>
    <time_frame>12 months ± 14 days</time_frame>
    <description>EQ-5D is a participant answered questionnaire scoring 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome.
EQ-5D Index scores based on EQ-5D questionnaire were calculated for participants ≥14 years of age, at screening, 6 months, and at termination visit. Changes in scores at 6 months and termination were also calculated.
A relatively higher score represents better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemophilia-specific Quality of Life Questionnaire for Adults (Haem-A-QoL) ≥ 16 Years Old</measure>
    <time_frame>12 months ± 14 days</time_frame>
    <description>The Haem-A-QoL instrument has been developed and used in Hemophilia A patients. As a hemophilia-specific instrument, this measure assesses very specific aspects of dealing with hemophilia. The areas covered by this instrument are: Physical Health (PH), Sports &amp; Leisure (S&amp;L), School &amp; Work (W&amp;S), Dealing with Hemophilia (Dealing), Family Planning (FP), Feeling, Relationships (R'ships), Treatment, View, and Outlook for the Future (Future). A Haem-A-QoL Total Score (Total) was also calculated. For the Haem-A-QoL, higher scores indicate a worse quality of life. Scores on a scale range between 0 and 100.
Haem-A-QoL scores at screening, 6 months, and at termination visit were collected. Changes in scores at 6 months and termination were also calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemophilia-specific Quality of Life Questionnaire for Children and Adolescents &lt; 16 Years Old (Haemo-QoL) - Parent's Evaluation</measure>
    <time_frame>12 months ± 14 days</time_frame>
    <description>The Haemo-QoL is a quality of life (QoL) assessment instrument for children and adolescents with haemophilia. As a hemophilia-specific instrument, this measure assesses very specific aspects of dealing with hemophilia. The areas covered by this instrument are: Physical Health (PH), Sports &amp; School (S&amp;S), Dealing with Hemophilia (Dealing), Family, Feeling, Relationships (R'ships), Treatment, View, Outlook for the Future (Future), Friends, Others, and Support. A Haemo-QoL Total Score (Total) was also calculated. For the Haemo-QoL, higher scores indicate a worse quality of life. Scores on a scale range between 0 and 100.
Haemo-QoL scores at screening, 6 months, and at termination visit were collected. Changes in scores at 6 months and termination were also calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemophilia-specific Quality of Life Questionnaire for Children and Adolescents &lt; 16 Years Old (Haemo-QoL) - Child's Evaluation</measure>
    <time_frame>12 months ± 14 days</time_frame>
    <description>The Haemo-QoL is a quality of life (QoL) assessment instrument for children and adolescents with haemophilia. As a hemophilia-specific instrument, this measure assesses very specific aspects of dealing with hemophilia. The areas covered by this instrument are: Physical Health (PH), Sports &amp; School (S&amp;S), Dealing with Hemophilia (Dealing), Family, Feeling, Relationships (R'ships), Treatment, View, Outlook for the Future (Future), Friends, Others, and Support. A Haemo-QoL Total Score (Total) was also calculated. For the Haemo-QoL, higher scores indicate a worse quality of life. Scores on a scale range between 0 and 100.
Haemo-QoL scores at screening, 6 months, and at termination visit were collected. Changes in scores at 6 months and termination were also calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HRQoL) - General Pain Assessment Using a Visual Analogue Scale (VAS) in Adults and Adolescents ≥12 Years Old</measure>
    <time_frame>Baseline, 6 months and 12 months ± 14 days</time_frame>
    <description>General pain was assessed using a VAS pain scale at screening, 6 months, and at termination. Unlike the VAS pain assessment for pain of bleeding episodes (Outcome above), this general pain assessment did not take use of analgesics into account. For the pain scale, a higher number indicates worse pain.
The visual analog scale ranges from 0 to 100 where the endpoints are labeled 'Worst imaginable health state' (=0) and 'Best imaginable health state' (=100). A positive change from baseline indicates improvement.
Change in VAS scores at 6 months and study termination were also compared relative to Baseline/Screening scores (ie, (Baseline/Screening VAS score) - (VAS score at 6 months and study termination).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HRQoL) - General Pain Assessment Using a Visual Analogue Scale (VAS) in Pediatrics &lt;12 Years Old</measure>
    <time_frame>Baseline, 6 months and 12 months ± 14 days</time_frame>
    <description>General pain was assessed using the children's VAS pain scale (a facial expression scale with one end marked as no pain and the opposite end marked as the worst possible pain). Assessments were done at the screening, 6 months, and termination visits.
Scores on the children's VAS scale are presented as:
No Pain
Mild Pain
Moderate pain
Severe pain
Very severe pain
Unlike the VAS pain assessment for pain of bleeding episodes (Outcome above), this general pain assessment did not take use of analgesics into account.
Change in VAS scores at 6 months and study termination were also compared relative to Baseline/Screening scores (ie, (Baseline/Screening VAS score) - (VAS score at 6 months and study termination).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Hemophilia A or B With Inhibitors</condition>
  <condition>Hemophilia A</condition>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>Prophylaxis arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>On-demand arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)</intervention_name>
    <description>85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
    <arm_group_label>Prophylaxis arm</arm_group_label>
    <other_name>FEIBA NF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)</intervention_name>
    <description>FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
    <arm_group_label>On-demand arm</arm_group_label>
    <other_name>FEIBA NF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated informed consent form by the participant or the participant's legally
             authorized representative

          -  The participant is ≥ 4 to ≤ 65 years of age

          -  The participant has a Karnofsky performance score of ≥ 60

          -  Hemophilia A and B of any severity, with documented history of high-titer inhibitor (&gt;
             5 Bethesda unit (BU)) for at least 12 months; or, if inhibitor titer is ≤ 5 BU, and
             the participant is refractory with increased dosing of either factor VIII (FVIII) or
             factor IX (FIX), as demonstrated from the participant's medical history

          -  Currently being treated on an on-demand basis for treatment of bleeding episodes

          -  Adequate venous access, with or without central venous device

          -  ≥ 12 bleeding episodes requiring treatment with by-passing agents in the past 12
             months, based on medical history

          -  Competent in-home treatment and infusion therapy

          -  Currently using bypassing agents (activated prothrombin complex concentrate (APCC) or
             recombinant activated factor VII (rFVIIa)) for treatment of bleeding episodes

          -  HCV-, either by antibody testing or polymerase chain reaction (PCR); or HCV+ with
             stable hepatic disease

          -  HIV-, or HIV+ with stable disease and CD4 count &gt; 200 cells/mm3 at screening

          -  Female participant of childbearing potential, presents with a negative serum pregnancy
             test, and agrees to employ adequate birth control measures for the duration of the
             study

        Exclusion Criteria:

          -  Currently receiving immune tolerance induction (ITI)

          -  Currently on regular prophylactic therapy to prevent bleeding episodes

          -  Clinically symptomatic liver disease (e.g. diagnosis of cirrhosis [confirmed by liver
             biopsy], portal vein hypertension, ascites, prothrombin time (PT) 5 seconds above
             upper limit of normal)

          -  Platelet count &lt; 100,000/ml

          -  Planned elective surgery during participation in this study

          -  Participant is currently participating in another clinical study and has received an
             investigational product or device within 30 days prior to study entry

          -  Planned use of pegylated or non-pegylated alpha-interferon with or without ribavirin
             for HCV infected participants or planned use of a protease inhibitor for HIV infected
             participants. Participants currently taking any of these medications for a 30-day
             course are eligible.

          -  Clinically significant increase in D-dimer levels from historical baseline and/or
             associated with chronic liver disease or clinically evident thromboembolic event

          -  Known hypersensitivity to anti-inhibitor coagulant complexes (AICCs)

          -  Currently treated with a systemic immunomodulating drug

          -  Prior history of thromboembolic event: acute myocardial infarction, deep vein
             thrombosis, or pulmonary embolism

          -  Diagnosis of advanced atherosclerosis, malignancy and/or other diseases that may
             increase the participant's risk of thromboembolic complications

          -  Clinically significant medical, psychiatric, or cognitive illness, or recreational
             drug/alcohol use that, in the opinion of the investigator, would affect participant
             safety or compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wing-Yen Wong, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Healthcare Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kirov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Japan</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Norway</country>
  </removed_countries>
  <results_reference>
    <citation>Antunes SV, Tangada S, Stasyshyn O, Mamonov V, Phillips J, Guzman-Becerra N, Grigorian A, Ewenstein B, Wong WY. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia. 2014 Jan;20(1):65-72. doi: 10.1111/hae.12246. Epub 2013 Aug 1.</citation>
    <PMID>23910578</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2009</study_first_submitted>
  <study_first_submitted_qc>February 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2009</study_first_posted>
  <results_first_submitted>January 30, 2014</results_first_submitted>
  <results_first_submitted_qc>January 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 14, 2014</results_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemophilia A</keyword>
  <keyword>Factor VIII Inhibitor</keyword>
  <keyword>Factor IX Inhibitor</keyword>
  <keyword>Hemophilia B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Feiba</mesh_term>
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment was conducted in Europe, North America, Asia-Pacific, and South America at 17 clinical sites beginning in March 2009.</recruitment_details>
      <pre_assignment_details>52 participants were enrolled. Sixteen participants discontinued, (ten were screen failures and six were withdrawn before randomization (2 sponsor's decision- inhibitors, 3 withdrew consent, and 1 due to investigator decision to have participant on prophylaxis). Therefore 36 participants were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>On-demand Arm</title>
          <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : Standard FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
        </group>
        <group group_id="P2">
          <title>Prophylaxis Arm</title>
          <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>planned surgery</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>On-demand Arm</title>
          <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : Standard FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
        </group>
        <group group_id="B2">
          <title>Prophylaxis Arm</title>
          <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.1" spread="15.2"/>
                    <measurement group_id="B2" value="25.6" spread="15.4"/>
                    <measurement group_id="B3" value="27.4" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Croatia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction in Annualized Bleeding Episode Rate (ABR) Among Participants Receiving Prophylactic Treatment as Compared to Those Treated On-demand</title>
        <description>Participants were Randomized to Receive 1 of the 2 Following Treatment Regimens:
On-Demand: FEIBA NF dose &amp; dosing interval as prescribed by treating physician
Prophylaxis: 85 ± 15 U/kg of FEIBA NF every other day during 12-month prophylactic period
Annualized rate of bleeding episodes was calculated as:
(Number of bleeding episodes/observed treatment period in days) * 365.25</description>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Efficacy Intent to Treat Analysis Dataset:
Dataset consists of data from all randomized participants. Dataset includes those who discontinued FEIBA NF but did not withdraw informed consent and were willing to continue providing data. For these participants, only the data collected before FEIBA NF discontinuation is included.</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated): FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Annualized Bleeding Episode Rate (ABR) Among Participants Receiving Prophylactic Treatment as Compared to Those Treated On-demand</title>
          <description>Participants were Randomized to Receive 1 of the 2 Following Treatment Regimens:
On-Demand: FEIBA NF dose &amp; dosing interval as prescribed by treating physician
Prophylaxis: 85 ± 15 U/kg of FEIBA NF every other day during 12-month prophylactic period
Annualized rate of bleeding episodes was calculated as:
(Number of bleeding episodes/observed treatment period in days) * 365.25</description>
          <population>Efficacy Intent to Treat Analysis Dataset:
Dataset consists of data from all randomized participants. Dataset includes those who discontinued FEIBA NF but did not withdraw informed consent and were willing to continue providing data. For these participants, only the data collected before FEIBA NF discontinuation is included.</population>
          <units>bleeds/year</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7" spread="1.8" lower_limit="17.7" upper_limit="50.0"/>
                    <measurement group_id="O2" value="7.9" spread="1.8" lower_limit="2.9" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: μ(on-demand) = μ(prophylaxis) Versus H1: μ(on-demand) ≠ μ(prophylaxis) (Where H0 implies no difference in mean bleeding episode rate between prophylaxis and on-demand treatment arms and H1 implies otherwise. This test was performed at a significance level of 5%, two-sided, two sample)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Two-sample, two-sided t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Bleeding Rate by Treatment Regimen, Bleeding Etiology, and Bleed Type</title>
        <description>Spontaneous includes unknown/undermined etiology</description>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Efficacy Intent to Treat Analysis Dataset:
Dataset consists of data from all randomized participants. Dataset includes those who discontinued FEIBA NF but did not withdraw informed consent and were willing to continue providing data. For these participants, only the data collected before FEIBA NF discontinuation is included.</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated): FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Bleeding Rate by Treatment Regimen, Bleeding Etiology, and Bleed Type</title>
          <description>Spontaneous includes unknown/undermined etiology</description>
          <population>Efficacy Intent to Treat Analysis Dataset:
Dataset consists of data from all randomized participants. Dataset includes those who discontinued FEIBA NF but did not withdraw informed consent and were willing to continue providing data. For these participants, only the data collected before FEIBA NF discontinuation is included.</population>
          <units>Bleeds per year</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Spontaneous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" lower_limit="10.9" upper_limit="43.5"/>
                    <measurement group_id="O2" value="5.6" lower_limit="2.9" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Traumatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="1.9" upper_limit="10.7"/>
                    <measurement group_id="O2" value="2.5" lower_limit="0.0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" lower_limit="14.1" upper_limit="46.9"/>
                    <measurement group_id="O2" value="6.0" lower_limit="2.9" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Joint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="1.0" upper_limit="4.9"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spontaneous Joint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6" lower_limit="9.9" upper_limit="40.8"/>
                    <measurement group_id="O2" value="4.5" lower_limit="2.9" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spontaneous Non-Joint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Traumatic Joint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="1.0" upper_limit="7.1"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Traumatic Non-Joint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Bleeding Etiologies, and Bleed Types</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7" lower_limit="17.7" upper_limit="50.0"/>
                    <measurement group_id="O2" value="7.9" lower_limit="2.9" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differences in Mean Transformed Annualized Bleeding Rate Between On-Demand and Prophylaxis Treatment Regimens by Bleeding Etiology, and Bleeding Type</title>
        <description>Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X′ = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the t-test.
The difference in mean transformed ABRs was used to perform statistical tests and generate p-values at a significance level of 5%
Participants were Randomized to Receive 1 of the 2 Following Treatment Regimens:
On-Demand: FEIBA NF dose &amp; dosing interval as prescribed by treating physician
Prophylaxis: 85 ± 15 U/kg of FEIBA NF every other day during 12-month prophylactic period</description>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Efficacy Intent to Treat Analysis Dataset</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm Versus Prophylaxis Arm</title>
            <description>On-demand arm: Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician
Prophylaxis arm: Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Mean Transformed Annualized Bleeding Rate Between On-Demand and Prophylaxis Treatment Regimens by Bleeding Etiology, and Bleeding Type</title>
          <description>Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X′ = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the t-test.
The difference in mean transformed ABRs was used to perform statistical tests and generate p-values at a significance level of 5%
Participants were Randomized to Receive 1 of the 2 Following Treatment Regimens:
On-Demand: FEIBA NF dose &amp; dosing interval as prescribed by treating physician
Prophylaxis: 85 ± 15 U/kg of FEIBA NF every other day during 12-month prophylactic period</description>
          <population>Efficacy Intent to Treat Analysis Dataset</population>
          <units>(bleeds/year)^(1/2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Spontaneous Bleeds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Traumatic Bleeds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Bleeds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Joint Bleeds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spontaneous Joint Bleeds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spontaneous Non-Joint Bleeds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Traumatic Joint Bleeds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Traumatic Non-Joint Bleeds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Spontaneous Bleeds</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>Two-sample, two-sided t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Traumatic Bleeds</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0199</p_value>
            <method>Two-sample, two-sided t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Joint Bleeds</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Two-sample, two-sided t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Non-Joint Bleeds</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0227</p_value>
            <method>Two-sample, two-sided t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Spontaneous Joint Bleeds</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0013</p_value>
            <method>Two-sample, two-sided t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Spontaneous Non-Joint Bleeds</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0030</p_value>
            <method>Two-sample, two-sided t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Traumatic Joint Bleeds</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0254</p_value>
            <method>Two-sample, two-sided t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Traumatic Non-Joint Bleeds</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9322</p_value>
            <method>Two-sample, two-sided t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Bleeding Rate for New Target Joints</title>
        <description>Target joints are ≥4 bleeds/6 months in any one of the following joints: ankles, knees, elbows, and hips; a target joint bleeding episode refers to an individual anatomical location.</description>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Efficacy Intent to Treat Analysis Dataset:
Dataset consists of data from all randomized participants. Dataset includes those who discontinued FEIBA NF but did not withdraw informed consent and were willing to continue providing data. For these participants, only the data collected before FEIBA NF discontinuation is included.</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated): FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Bleeding Rate for New Target Joints</title>
          <description>Target joints are ≥4 bleeds/6 months in any one of the following joints: ankles, knees, elbows, and hips; a target joint bleeding episode refers to an individual anatomical location.</description>
          <population>Efficacy Intent to Treat Analysis Dataset:
Dataset consists of data from all randomized participants. Dataset includes those who discontinued FEIBA NF but did not withdraw informed consent and were willing to continue providing data. For these participants, only the data collected before FEIBA NF discontinuation is included.</population>
          <units>Bleeds per year</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="0.0" upper_limit="12.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differences in Mean Transformed Annualized Bleeding Rate Between On-Demand and Prophylaxis Treatment Regimens: New Target Joints</title>
        <description>Annualized bleed rates (ABRs) were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X′ = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using a two-sample, two-sided t-test.
The difference in mean transformed ABRs was used to perform statistical tests and generate p-values at a significance level of 5%</description>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Efficacy Intent to Treat Analysis Dataset:
Dataset consists of data from all randomized participants. Dataset includes those who discontinued FEIBA NF but did not withdraw informed consent and were willing to continue providing data. For these participants, only the data collected before FEIBA NF discontinuation is included.</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm Versus Prophylaxis Arm</title>
            <description>On-demand arm: Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated): FEIBA NF dose and dosing interval as prescribed by the treating physician
Prophylaxis arm: Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Mean Transformed Annualized Bleeding Rate Between On-Demand and Prophylaxis Treatment Regimens: New Target Joints</title>
          <description>Annualized bleed rates (ABRs) were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X′ = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using a two-sample, two-sided t-test.
The difference in mean transformed ABRs was used to perform statistical tests and generate p-values at a significance level of 5%</description>
          <population>Efficacy Intent to Treat Analysis Dataset:
Dataset consists of data from all randomized participants. Dataset includes those who discontinued FEIBA NF but did not withdraw informed consent and were willing to continue providing data. For these participants, only the data collected before FEIBA NF discontinuation is included.</population>
          <units>(bleeds/year)^(1/2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0271</p_value>
            <method>Two-sample, two-sided t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of New Target Joints</title>
        <description>Target Joints are defined as ≥4 bleeds/6 months in any one of the following joints: ankles, knees, elbows and hips</description>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Efficacy Intent to Treat Analysis Dataset:
Dataset consists of data from all randomized participants. Dataset includes those who discontinued FEIBA NF but did not withdraw informed consent and were willing to continue providing data. For these participants, only the data collected before FEIBA NF discontinuation is included.</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Number of New Target Joints</title>
          <description>Target Joints are defined as ≥4 bleeds/6 months in any one of the following joints: ankles, knees, elbows and hips</description>
          <population>Efficacy Intent to Treat Analysis Dataset:
Dataset consists of data from all randomized participants. Dataset includes those who discontinued FEIBA NF but did not withdraw informed consent and were willing to continue providing data. For these participants, only the data collected before FEIBA NF discontinuation is included.</population>
          <units>new target joints</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Objective Clinical Symptoms- Visual Analog Scale (VAS): Pain in Adolescents and Adults (≥12 Years Old)</title>
        <description>Pain caused by a bleeding episode in adolescents and adults (≥12 years old) was measured at pre-infusion (pre-inf) and at 6 ± 0.5 hours (h) and 24 ± 1 h post-infusion (post-inf) (after the last infusion given to treat a bleeding episode) on the VAS pain scale in millimeters from 0 (no pain) to 100 (worst possible pain). For analysis purposes, if short acting analgesics (duration of activity approximately 6 ± 0.5 h) were used, pain was assigned the highest possible score (100). Pain assessment occurred after each infusion related to single bleeding episodes. In case participants required an additional infusion within 24h, pain was assessed 6 ± 0.5 h and 24 ±1 h following the subsequent infusion.
Change in VAS scores at 6 ± 0.5 h and 24 ±1 h post-infusion were also compared relative to pre-infusion VAS scores (ie, (pre-infusion VAS score) - (post-infusion VAS score)).</description>
        <time_frame>Throughout the study period, 12 months ± 14 days</time_frame>
        <population>Additional evaluations for bleeding episodes in the intent-to-treat analysis dataset: consists of all participants with at least 1 bleeding episode treated with investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Objective Clinical Symptoms- Visual Analog Scale (VAS): Pain in Adolescents and Adults (≥12 Years Old)</title>
          <description>Pain caused by a bleeding episode in adolescents and adults (≥12 years old) was measured at pre-infusion (pre-inf) and at 6 ± 0.5 hours (h) and 24 ± 1 h post-infusion (post-inf) (after the last infusion given to treat a bleeding episode) on the VAS pain scale in millimeters from 0 (no pain) to 100 (worst possible pain). For analysis purposes, if short acting analgesics (duration of activity approximately 6 ± 0.5 h) were used, pain was assigned the highest possible score (100). Pain assessment occurred after each infusion related to single bleeding episodes. In case participants required an additional infusion within 24h, pain was assessed 6 ± 0.5 h and 24 ±1 h following the subsequent infusion.
Change in VAS scores at 6 ± 0.5 h and 24 ±1 h post-infusion were also compared relative to pre-infusion VAS scores (ie, (pre-infusion VAS score) - (post-infusion VAS score)).</description>
          <population>Additional evaluations for bleeding episodes in the intent-to-treat analysis dataset: consists of all participants with at least 1 bleeding episode treated with investigational product.</population>
          <units>Scores on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <units_analyzed>Bleeding episodes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Bleeding episodes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="522"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Infusion (N= 513, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0" spread="43.0" lower_limit="12.0" upper_limit="55.0"/>
                    <measurement group_id="O2" value="49.5" spread="46.9" lower_limit="34.7" upper_limit="81.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 ± 0.5 hours post-infusion (N= 522, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="33.0" lower_limit="4.0" upper_limit="37.0"/>
                    <measurement group_id="O2" value="33.8" spread="44.6" lower_limit="8.0" upper_limit="52.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 ± 1 hours post-infusion (N= 512,131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="13.0" lower_limit="1.0" upper_limit="14.0"/>
                    <measurement group_id="O2" value="6.2" spread="19.0" lower_limit="1.0" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change (Pre-Inf to 6h post-inf) (N= 509, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="4.0" upper_limit="21.8"/>
                    <measurement group_id="O2" value="19.4" lower_limit="5.0" upper_limit="41.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change (Pre-Inf to 24h post-inf) (N= 489, 102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" lower_limit="8.0" upper_limit="39.6"/>
                    <measurement group_id="O2" value="37.8" lower_limit="17.0" upper_limit="75.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Clinical Symptoms - Visual Analog Scale (VAS): Pain in Pediatrics (&lt;12 Years Old)</title>
        <description>Pain caused by a bleeding episode (BE) in pediatric participants (&lt;12 years old) was measured at pre-infusion (pre-inf) and at 6 ± 0.5 h and 24 ± 1 h post-infusion (post-inf) (after the last infusion given to treat a bleeding episode) using the children’s VAS pain scale (a facial expression scale with one end marked as no pain and the opposite end marked as the worst possible pain). For analysis purposes, if short acting analgesics (duration of activity approximately 6 ± 0.5 h) were used, pain was assigned the highest possible score (worst possible pain).
Scores on the children's VAS scale are presented as:
No Pain
Mild Pain
Moderate pain
Severe pain
Very severe pain</description>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Additional evaluations for bleeding episodes in the intent-to-treat analysis dataset: consists of all participants with at least 1 bleeding episode treated with investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Clinical Symptoms - Visual Analog Scale (VAS): Pain in Pediatrics (&lt;12 Years Old)</title>
          <description>Pain caused by a bleeding episode (BE) in pediatric participants (&lt;12 years old) was measured at pre-infusion (pre-inf) and at 6 ± 0.5 h and 24 ± 1 h post-infusion (post-inf) (after the last infusion given to treat a bleeding episode) using the children’s VAS pain scale (a facial expression scale with one end marked as no pain and the opposite end marked as the worst possible pain). For analysis purposes, if short acting analgesics (duration of activity approximately 6 ± 0.5 h) were used, pain was assigned the highest possible score (worst possible pain).
Scores on the children's VAS scale are presented as:
No Pain
Mild Pain
Moderate pain
Severe pain
Very severe pain</description>
          <population>Additional evaluations for bleeding episodes in the intent-to-treat analysis dataset: consists of all participants with at least 1 bleeding episode treated with investigational product.</population>
          <units>Bleeding episodes</units>
          <param>Number</param>
          <units_analyzed>Bleeding episodes (BEs)</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Bleeding episodes (BEs)</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Infusion (N= 54, 8) - No Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Infusion (N= 54, 8) - Mild Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Infusion (N= 54, 8) - Moderate Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Infusion (N= 54, 8) - Severe Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Infusion (N= 54, 8) - Very Severe Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 ± 0.5 h post-infusion (N= 74, 8) - No Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>± 0.5 h post-infusion (N= 74, 8) - Mild Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>± 0.5 h post-infusion (N= 74, 8) - Moderate Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>± 0.5 h post-infusion (N= 74, 8) - Severe Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>± 0.5 h post-infusion (N= 74, 8)- Very Severe Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 ± 1 h post-infusion (N= 77, 9) - No Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 ± 1 h post-infusion (N= 77, 9) - Mild Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 ± 1 h post-infusion (N= 77, 9) - Moderate Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 ± 1 h post-infusion (N= 77, 9) - Severe Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24± 1h post-infusion (N = 77, 9) -Very Severe Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Clinical Symptoms - Range of Motion (ROM)</title>
        <description>ROM was measured using a goniometer for 3 key joints (ie, ankles, knees, and elbows) at screening, month 6, and termination (end of study visit)</description>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated): FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Clinical Symptoms - Range of Motion (ROM)</title>
          <description>ROM was measured using a goniometer for 3 key joints (ie, ankles, knees, and elbows) at screening, month 6, and termination (end of study visit)</description>
          <population>Safety Analysis Set</population>
          <units>degrees</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Left Elbow - Extension: Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="0.0" upper_limit="45.0"/>
                    <measurement group_id="O2" value="10.0" lower_limit="0.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Elbow - Extension: Month 6 (n = 18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="0.0" upper_limit="41.0"/>
                    <measurement group_id="O2" value="8.0" lower_limit="0.0" upper_limit="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Elbow - Extension: Termination (n = 17,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="0.0" upper_limit="41.0"/>
                    <measurement group_id="O2" value="15.5" lower_limit="0.0" upper_limit="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Elbow - Flexion: Screening (n = 19,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.0" lower_limit="90.0" upper_limit="140.0"/>
                    <measurement group_id="O2" value="115.0" lower_limit="80.0" upper_limit="140.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Elbow - Flexion: Month 6 (n = 18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.0" lower_limit="90.0" upper_limit="140.0"/>
                    <measurement group_id="O2" value="125.0" lower_limit="72.5" upper_limit="143.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Elbow - Flexion: Termination (n = 17,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.0" lower_limit="90.0" upper_limit="140.0"/>
                    <measurement group_id="O2" value="125.0" lower_limit="75.0" upper_limit="145.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Elbow - Pronation: Screening (n = 18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.0" lower_limit="55.0" upper_limit="90.0"/>
                    <measurement group_id="O2" value="55.0" lower_limit="22.5" upper_limit="77.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Elbow - Pronation: Month 6 (n = 17,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="60.0" upper_limit="90.0"/>
                    <measurement group_id="O2" value="67.5" lower_limit="35.0" upper_limit="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Elbow - Pronation: Termination (n = 17,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0" lower_limit="60.0" upper_limit="90.0"/>
                    <measurement group_id="O2" value="65.0" lower_limit="30.0" upper_limit="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Elbow - Supination: Screening (n = 18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="50.0" upper_limit="90.0"/>
                    <measurement group_id="O2" value="42.5" lower_limit="17.5" upper_limit="77.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Elbow - Supination: Month 6 (n = 17,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="50.0" upper_limit="90.0"/>
                    <measurement group_id="O2" value="60.0" lower_limit="35.0" upper_limit="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Elbow - Supination: Termination (n = 17,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="50.0" upper_limit="90.0"/>
                    <measurement group_id="O2" value="70.0" lower_limit="35.0" upper_limit="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Elbow - Extension: Screening (n = 19,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="0.0" upper_limit="50.0"/>
                    <measurement group_id="O2" value="10.0" lower_limit="0.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Elbow - Extension: Month 6 (n = 18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" lower_limit="0.0" upper_limit="50.0"/>
                    <measurement group_id="O2" value="10.0" lower_limit="0.0" upper_limit="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Elbow - Extension: Termination (n = 18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" lower_limit="0.0" upper_limit="45.0"/>
                    <measurement group_id="O2" value="20.0" lower_limit="0.0" upper_limit="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Elbow - Flexion: Screening (n = 19,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.0" lower_limit="105.0" upper_limit="140.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="80.0" upper_limit="130.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Elbow - Flexion: Month 6 (n = 18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.5" lower_limit="110.0" upper_limit="140.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="85.0" upper_limit="136.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Elbow - Flexion: Termination (n = 18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.0" lower_limit="110.0" upper_limit="140.0"/>
                    <measurement group_id="O2" value="99.0" lower_limit="70.0" upper_limit="127.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Elbow - Pronation: Screening (n = 18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="55.0" upper_limit="90.0"/>
                    <measurement group_id="O2" value="57.5" lower_limit="27.5" upper_limit="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Elbow - Pronation: Month 6 (n = 17,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="55.0" upper_limit="90.0"/>
                    <measurement group_id="O2" value="72.5" lower_limit="40.0" upper_limit="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Elbow - Pronation: Termination (n = 18,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.5" lower_limit="55.0" upper_limit="90.0"/>
                    <measurement group_id="O2" value="70.0" lower_limit="40.0" upper_limit="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Elbow - Supination: Screening (n = 18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="45.0" upper_limit="90.0"/>
                    <measurement group_id="O2" value="52.5" lower_limit="20.0" upper_limit="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Elbow - Supination: Month 6 (n = 17,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="45.0" upper_limit="90.0"/>
                    <measurement group_id="O2" value="72.5" lower_limit="30.0" upper_limit="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Elbow - Supination: Termination (n = 18,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="45.0" upper_limit="90.0"/>
                    <measurement group_id="O2" value="70.0" lower_limit="30.0" upper_limit="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Knee - Extension: Screening (n = 18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="5.0" upper_limit="90.0"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.0" upper_limit="55.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Knee - Extension: Month 6 (n = 17,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="5.0" upper_limit="70.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Knee - Extension: Termination (n = 18,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="5.0" upper_limit="90.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Knee - Flexion: Screening (n = 19,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="80.0" upper_limit="130.0"/>
                    <measurement group_id="O2" value="90.0" lower_limit="65.0" upper_limit="115.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Knee - Flexion: Month 6 (n = 18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.5" lower_limit="80.0" upper_limit="130.0"/>
                    <measurement group_id="O2" value="97.5" lower_limit="65.0" upper_limit="125.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Knee - Flexion: Termination (n = 18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.0" lower_limit="60.0" upper_limit="130.0"/>
                    <measurement group_id="O2" value="92.5" lower_limit="70.0" upper_limit="125.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Knee - Extension: Screening (n = 18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" lower_limit="10.0" upper_limit="90.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="0.0" upper_limit="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Knee - Extension: Month 6 (n = 17,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="10.0" upper_limit="90.0"/>
                    <measurement group_id="O2" value="10.0" lower_limit="2.0" upper_limit="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Knee - Extension: Termination (n = 18,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" lower_limit="10.0" upper_limit="90.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="0.0" upper_limit="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Knee - Flexion: Screening (n = 19,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="20.0" upper_limit="122.0"/>
                    <measurement group_id="O2" value="80.0" lower_limit="60.0" upper_limit="125.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Knee - Flexion: Month 6 (n = 18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="20.0" upper_limit="130.0"/>
                    <measurement group_id="O2" value="82.5" lower_limit="56.0" upper_limit="127.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Knee - Flexion: Termination (n = 18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0" lower_limit="20.0" upper_limit="120.0"/>
                    <measurement group_id="O2" value="87.5" lower_limit="56.0" upper_limit="127.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Ankle - Dorsiflexion: Screening (n = 18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="15.0" upper_limit="30.0"/>
                    <measurement group_id="O2" value="17.5" lower_limit="9.0" upper_limit="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Ankle - Dorsiflexion: Month 6 (n = 17,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="11.0" upper_limit="35.0"/>
                    <measurement group_id="O2" value="17.5" lower_limit="8.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Ankle - Dorsiflexion: Termination (n = 17,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="11.0" upper_limit="25.0"/>
                    <measurement group_id="O2" value="20.0" lower_limit="5.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Ankle - Plantarflexion: Screening (n = 18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5" lower_limit="30.0" upper_limit="40.0"/>
                    <measurement group_id="O2" value="30.0" lower_limit="10.0" upper_limit="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Ankle - Plantarflexion: Month 6 (n = 17,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0" lower_limit="25.0" upper_limit="35.0"/>
                    <measurement group_id="O2" value="30.0" lower_limit="15.0" upper_limit="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Ankle - Plantarflexion: Termination (n=17,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" lower_limit="30.0" upper_limit="40.0"/>
                    <measurement group_id="O2" value="30.0" lower_limit="15.0" upper_limit="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Ankle - Pronation: Screening (n = 19,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="10.0" upper_limit="20.0"/>
                    <measurement group_id="O2" value="15.0" lower_limit="10.0" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Ankle - Pronation: Month 6 (n = 18,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="10.0" upper_limit="20.0"/>
                    <measurement group_id="O2" value="15.0" lower_limit="10.0" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Ankle - Pronation: Termination (n = 18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="10.0" upper_limit="20.0"/>
                    <measurement group_id="O2" value="12.5" lower_limit="10.0" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Ankle - Supination: Screening (n = 19,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="10.0" upper_limit="30.0"/>
                    <measurement group_id="O2" value="15.0" lower_limit="10.0" upper_limit="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Ankle - Supination: Month 6 (n = 18,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="20.0" upper_limit="30.0"/>
                    <measurement group_id="O2" value="25.0" lower_limit="10.0" upper_limit="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Ankle - Supination: Termination (n = 18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="16.0" upper_limit="30.0"/>
                    <measurement group_id="O2" value="20.0" lower_limit="10.0" upper_limit="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Ankle - Dorsiflexion: Screening (n = 18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="10.0" upper_limit="20.0"/>
                    <measurement group_id="O2" value="20.0" lower_limit="7.5" upper_limit="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Ankle - Dorsiflexion: Month 6 (n = 17,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="15.0" upper_limit="20.0"/>
                    <measurement group_id="O2" value="25.0" lower_limit="6.0" upper_limit="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Ankle - Dorsiflexion: Termination (n= 17,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="14.0" upper_limit="20.0"/>
                    <measurement group_id="O2" value="20.0" lower_limit="10.0" upper_limit="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Ankle - Plantarflexion: Screening (n= 18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" lower_limit="30.0" upper_limit="40.0"/>
                    <measurement group_id="O2" value="20.0" lower_limit="9.0" upper_limit="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Ankle - Plantarflexion: Month 6 (n= 17,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" lower_limit="25.0" upper_limit="40.0"/>
                    <measurement group_id="O2" value="23.0" lower_limit="10.0" upper_limit="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Ankle - Plantarflexion: Termination(n=17,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" lower_limit="25.0" upper_limit="40.0"/>
                    <measurement group_id="O2" value="21.0" lower_limit="10.0" upper_limit="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Ankle - Pronation: Screening (n = 19,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="10.0" upper_limit="15.0"/>
                    <measurement group_id="O2" value="10.0" lower_limit="10.0" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Ankle - Pronation: Month 6 (n= 18,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="10.0" upper_limit="20.0"/>
                    <measurement group_id="O2" value="10.0" lower_limit="10.0" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Ankle - Pronation: Termination (n= 18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="10.0" upper_limit="17.0"/>
                    <measurement group_id="O2" value="11.0" lower_limit="10.0" upper_limit="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Ankle - Supination: Screening (n = 19,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" lower_limit="10.0" upper_limit="30.0"/>
                    <measurement group_id="O2" value="20.0" lower_limit="10.0" upper_limit="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Ankle - Supination: Month 6 (n= 18,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="10.0" upper_limit="30.0"/>
                    <measurement group_id="O2" value="20.0" lower_limit="10.0" upper_limit="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Ankle - Supination: Termination (n= 18,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="10.0" upper_limit="30.0"/>
                    <measurement group_id="O2" value="20.0" lower_limit="10.0" upper_limit="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Hemostasis for Treatment of Bleeding Episodes- Overall Efficacy Rating at 6 Hours</title>
        <description>Number of rAHF-PFM-treated bleeding episodes with an assessment of hemostasis (4-point ordinal scale):
Excellent: Full pain relief &amp; bleeding cessation within ~6 hours of 1 infusion. Additional infusions may have been given to maintain hemostasis;
Good: Definite pain relief and/or improvement in bleeding within ~6 hours after infusion. Possibly requires &gt;1 infusion for complete resolution;
Fair: Probable or slight relief of pain &amp; slight improvement in bleeding within
~6 hours after infusion. Requires &gt;1 infusion for complete resolution;
None: No improvement or condition worsens</description>
        <time_frame>6 h ± 30 min post-infusion</time_frame>
        <population>Bleeding Episodes Analysis Set Consists of all participants who experienced a bleeding episode (BE)</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated): FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Hemostasis for Treatment of Bleeding Episodes- Overall Efficacy Rating at 6 Hours</title>
          <description>Number of rAHF-PFM-treated bleeding episodes with an assessment of hemostasis (4-point ordinal scale):
Excellent: Full pain relief &amp; bleeding cessation within ~6 hours of 1 infusion. Additional infusions may have been given to maintain hemostasis;
Good: Definite pain relief and/or improvement in bleeding within ~6 hours after infusion. Possibly requires &gt;1 infusion for complete resolution;
Fair: Probable or slight relief of pain &amp; slight improvement in bleeding within
~6 hours after infusion. Requires &gt;1 infusion for complete resolution;
None: No improvement or condition worsens</description>
          <population>Bleeding Episodes Analysis Set Consists of all participants who experienced a bleeding episode (BE)</population>
          <units>bleeding episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent (n = 16, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good (n = 19, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="355"/>
                    <measurement group_id="O2" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair (n = 15, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None (n = 6, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rating Not Done (n = 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Available (n = 0, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Hemostasis for Treatment of Bleeding Episodes- Overall Efficacy Rating at 24 Hours</title>
        <description>Number of rAHF-PFM-treated bleeding episodes with an assessment of hemostasis (4-point ordinal scale):
Excellent: Full pain relief &amp; bleeding cessation within ~24 hours of 1 infusion. Additional infusions may have been given to maintain hemostasis;
Good: Definite pain relief and/or improvement in bleeding within ~24 hours after infusion. Possibly requires &gt;1 infusion for complete resolution;
Fair: Probable or slight relief of pain &amp; slight improvement in bleeding within
~24 hours after infusion. Requires &gt;1 infusion for complete resolution;
None: No improvement or condition worsens</description>
        <time_frame>24 ± 1 h post-infusion</time_frame>
        <population>Bleeding Episodes Analysis Set Consists of all participants who experienced a bleeding episode (BE)</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated): FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Hemostasis for Treatment of Bleeding Episodes- Overall Efficacy Rating at 24 Hours</title>
          <description>Number of rAHF-PFM-treated bleeding episodes with an assessment of hemostasis (4-point ordinal scale):
Excellent: Full pain relief &amp; bleeding cessation within ~24 hours of 1 infusion. Additional infusions may have been given to maintain hemostasis;
Good: Definite pain relief and/or improvement in bleeding within ~24 hours after infusion. Possibly requires &gt;1 infusion for complete resolution;
Fair: Probable or slight relief of pain &amp; slight improvement in bleeding within
~24 hours after infusion. Requires &gt;1 infusion for complete resolution;
None: No improvement or condition worsens</description>
          <population>Bleeding Episodes Analysis Set Consists of all participants who experienced a bleeding episode (BE)</population>
          <units>bleeding episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent (n = 16, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good (n = 19, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="280"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair (n = 9, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None (n = 1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rating Not Done (n = 8, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Available (n = 0, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Weight Adjusted Dose to Control a Bleeding Episode</title>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Additional Evaluations for Bleeding Episodes Analysis Set
- Consists of all participants with at least 1 bleeding episode treated with investigational product, FEIBA NF.</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated): FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Total Weight Adjusted Dose to Control a Bleeding Episode</title>
          <population>Additional Evaluations for Bleeding Episodes Analysis Set
- Consists of all participants with at least 1 bleeding episode treated with investigational product, FEIBA NF.</population>
          <units>Units/kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4049.7" lower_limit="2324.5" upper_limit="7408.4"/>
                    <measurement group_id="O2" value="1524.9" lower_limit="293.2" upper_limit="2883.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0067</p_value>
            <method>Mann-Whitney tests (Wilcoxon-Rank Sum)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Bleeding Episode (BE) Which Required 1, 2, 3, or ≥4 Infusions to Control Bleeding</title>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Additional Evaluations for Bleeding Episodes Analysis Set
- Consists of all participants with at least 1 bleeding episode treated with investigational product, FEIBA NF.</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated): FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Bleeding Episode (BE) Which Required 1, 2, 3, or ≥4 Infusions to Control Bleeding</title>
          <population>Additional Evaluations for Bleeding Episodes Analysis Set
- Consists of all participants with at least 1 bleeding episode treated with investigational product, FEIBA NF.</population>
          <units>Bleeding Episodes (BEs)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="352"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 infusions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 infusions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥4 infusions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Abnormal Activated Partial Thromboplastin Time (aPTT) Assay Results</title>
        <description>The normal reference range of values for aPTT is 22.8 – 31 seconds.</description>
        <time_frame>Screening visit, Month 3, Month 6, Month 9, and Termination visit</time_frame>
        <population>Safety Analysis Set Participants with Clinically Significant Laboratory Results</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated): FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Abnormal Activated Partial Thromboplastin Time (aPTT) Assay Results</title>
          <description>The normal reference range of values for aPTT is 22.8 – 31 seconds.</description>
          <population>Safety Analysis Set Participants with Clinically Significant Laboratory Results</population>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening visit (n= 19, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3" lower_limit="63.1" upper_limit="75.1"/>
                    <measurement group_id="O2" value="68.5" lower_limit="61.0" upper_limit="73.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n= 14, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0" lower_limit="62.7" upper_limit="76.2"/>
                    <measurement group_id="O2" value="62.7" lower_limit="57.5" upper_limit="67.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n= 17, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2" lower_limit="64.6" upper_limit="72.1"/>
                    <measurement group_id="O2" value="65.6" lower_limit="62.6" upper_limit="69.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n= 17, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="64.6" upper_limit="77.9"/>
                    <measurement group_id="O2" value="68.1" lower_limit="58.1" upper_limit="73.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Termination visit (n= 18, 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.8" lower_limit="63.4" upper_limit="75.6"/>
                    <measurement group_id="O2" value="69.4" lower_limit="60.5" upper_limit="77.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Abnormal D-Dimer Assay Results</title>
        <description>The normal reference range of values for D-dimers is &lt;500 ng/mL.</description>
        <time_frame>Screening visit, Month 3, Month 6, Month 9, and Termination visit</time_frame>
        <population>Safety Analysis Set Participants with Clinically Significant Laboratory Results</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated): FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Abnormal D-Dimer Assay Results</title>
          <description>The normal reference range of values for D-dimers is &lt;500 ng/mL.</description>
          <population>Safety Analysis Set Participants with Clinically Significant Laboratory Results</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening visit (n= 7, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="862.0" lower_limit="647.0" upper_limit="1035.0"/>
                    <measurement group_id="O2" value="833.5" lower_limit="644.0" upper_limit="1164.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n= 7, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="690.0" lower_limit="561.0" upper_limit="830.0"/>
                    <measurement group_id="O2" value="1021.5" lower_limit="730.0" upper_limit="1633.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n= 9, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="969.0" lower_limit="753.0" upper_limit="1103.0"/>
                    <measurement group_id="O2" value="1032.0" lower_limit="652.0" upper_limit="1442.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n= 6, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="731.5" lower_limit="592.0" upper_limit="1398.0"/>
                    <measurement group_id="O2" value="1121.0" lower_limit="942.5" upper_limit="1448.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Termination visit (n= 5, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="813.0" lower_limit="695.0" upper_limit="1386.0"/>
                    <measurement group_id="O2" value="1031.0" lower_limit="872.0" upper_limit="1258.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Abnormal Fibrinogen Assay Results</title>
        <description>The normal reference range of values for fibrinogen is 200-400 mg/dL.</description>
        <time_frame>Screening visit, Month 3, Month 6, Month 9, and Termination visit</time_frame>
        <population>Safety Analysis Set Participants with Clinically Significant Laboratory Results</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Abnormal Fibrinogen Assay Results</title>
          <description>The normal reference range of values for fibrinogen is 200-400 mg/dL.</description>
          <population>Safety Analysis Set Participants with Clinically Significant Laboratory Results</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening visit (n= 4, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428.0" lower_limit="414.0" upper_limit="478.5"/>
                    <measurement group_id="O2" value="422.0" lower_limit="411.0" upper_limit="428.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n= 0, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There were no abnormal fibrinogen assay results for this arm/group at this time point</measurement>
                    <measurement group_id="O2" value="402.0" lower_limit="199.0" upper_limit="605.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n= 3, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="415.0" lower_limit="412.0" upper_limit="418.0"/>
                    <measurement group_id="O2" value="759.0" lower_limit="759.0" upper_limit="759.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n= 1, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="508.0" lower_limit="508.0" upper_limit="508.0"/>
                    <measurement group_id="O2" value="326.5" lower_limit="183.5" upper_limit="635.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Termination visit (n= 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="456.5" lower_limit="425.0" upper_limit="488.0"/>
                    <measurement group_id="O2" value="522.5" lower_limit="414.0" upper_limit="631.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Abnormal Fibrin Degradation Products (FDP) Assay Results</title>
        <description>The normal reference range of values for FDP is 0-5 ug/mL.</description>
        <time_frame>Screening visit, Month 3, Month 6, Month 9, and Termination visit</time_frame>
        <population>Safety Analysis Set Participants with Clinically Significant Laboratory Results</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Abnormal Fibrin Degradation Products (FDP) Assay Results</title>
          <description>The normal reference range of values for FDP is 0-5 ug/mL.</description>
          <population>Safety Analysis Set Participants with Clinically Significant Laboratory Results</population>
          <units>ug/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening visit (n= 1, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="16.0" upper_limit="16.0"/>
                    <measurement group_id="O2" value="12.0" lower_limit="8.0" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n= 0, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There were no abnormal fibrin degradation products assay results for this arm/group at this time point</measurement>
                    <measurement group_id="O2" value="8.0" lower_limit="8.0" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n= 1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="8.0" upper_limit="8.0"/>
                    <measurement group_id="O2" value="8.0" lower_limit="8.0" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n= 1, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="8.0" upper_limit="8.0"/>
                    <measurement group_id="O2" value="8.0" lower_limit="8.0" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Termination visit (n= 3, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="8.0" upper_limit="8.0"/>
                    <measurement group_id="O2" value="8.0" lower_limit="8.0" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Abnormal Prothrombin Fragment F 1.2 Assay Results</title>
        <description>The normal reference range of values for prothrombin fragment F 1.2 is 69-229 pmol/L.</description>
        <time_frame>Screening visit, Month 3, Month 6, Month 9, and Termination visit</time_frame>
        <population>Safety Analysis Set Participants with Clinically Significant Laboratory Results</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Abnormal Prothrombin Fragment F 1.2 Assay Results</title>
          <description>The normal reference range of values for prothrombin fragment F 1.2 is 69-229 pmol/L.</description>
          <population>Safety Analysis Set Participants with Clinically Significant Laboratory Results</population>
          <units>pmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening visit (n= 2, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="284.0" lower_limit="278.0" upper_limit="290.0"/>
                    <measurement group_id="O2" value="308.0" lower_limit="308.0" upper_limit="308.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n= 6, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="336.5" lower_limit="267.0" upper_limit="414.0"/>
                    <measurement group_id="O2" value="579.0" lower_limit="354.0" upper_limit="972.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n= 3, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="448.0" lower_limit="272.0" upper_limit="714.0"/>
                    <measurement group_id="O2" value="430.0" lower_limit="366.0" upper_limit="504.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n= 4, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="382.0" lower_limit="313.0" upper_limit="405.5"/>
                    <measurement group_id="O2" value="415.0" lower_limit="272.0" upper_limit="472.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Termination visit (n= 4, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252.5" lower_limit="250.0" upper_limit="265.0"/>
                    <measurement group_id="O2" value="643.0" lower_limit="376.0" upper_limit="1679.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Abnormal Prothrombin Time Assay Results</title>
        <description>The normal reference range of values for PT is 9.7-12.3 sec.</description>
        <time_frame>Screening visit, Month 3, Month 6, Month 9, and Termination visit</time_frame>
        <population>Safety Analysis Set Participants with Clinically Significant Laboratory Results</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Abnormal Prothrombin Time Assay Results</title>
          <description>The normal reference range of values for PT is 9.7-12.3 sec.</description>
          <population>Safety Analysis Set Participants with Clinically Significant Laboratory Results</population>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening visit (n= 1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="9.4" upper_limit="9.4"/>
                    <measurement group_id="O2" value="9.6" lower_limit="9.6" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n= 1, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="9.5" upper_limit="9.5"/>
                    <measurement group_id="O2" value="NA">There were no abnormal prothrombin time assay results for this arm/group at this time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n= 0, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There were no abnormal prothrombin time assay results for this arm/group at this time point</measurement>
                    <measurement group_id="O2" value="12.5" lower_limit="12.5" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n= 1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" lower_limit="12.7" upper_limit="12.7"/>
                    <measurement group_id="O2" value="13.6" lower_limit="13.6" upper_limit="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Termination visit (n= 0, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There were no abnormal prothrombin time assay results for this arm/group at this time point</measurement>
                    <measurement group_id="O2" value="13.4" lower_limit="13.4" upper_limit="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Abnormal Thrombin-Antithrombin III (TAT) Assay Results</title>
        <description>The normal reference range of values for TAT is 1-4.1 ug/L.</description>
        <time_frame>Screening visit, Month 3, Month 6, Month 9, and Termination visit</time_frame>
        <population>Safety Analysis Set Participants with Clinically Significant Laboratory Results</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Abnormal Thrombin-Antithrombin III (TAT) Assay Results</title>
          <description>The normal reference range of values for TAT is 1-4.1 ug/L.</description>
          <population>Safety Analysis Set Participants with Clinically Significant Laboratory Results</population>
          <units>ug/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening visit (n= 4, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="4.4" upper_limit="5.9"/>
                    <measurement group_id="O2" value="5.6" lower_limit="5.6" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n= 3, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="4.5" upper_limit="5.9"/>
                    <measurement group_id="O2" value="12.3" lower_limit="4.4" upper_limit="40.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n= 3, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="6.3" upper_limit="10.5"/>
                    <measurement group_id="O2" value="5.6" lower_limit="4.4" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (n= 0, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There were no abnormal Thrombin-Antithrombin III assay results for this arm/group at this time point</measurement>
                    <measurement group_id="O2" value="6.0" lower_limit="5.6" upper_limit="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Termination visit (n= 2, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" lower_limit="8.0" upper_limit="12.5"/>
                    <measurement group_id="O2" value="5.6" lower_limit="5.1" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Serology From Screening Visit and Study Termination Visit: Hepatitis A, Hepatitis B, and Hepatitis C</title>
        <description>Hepatitis A Virus Antibody (HAV Ab)
Hepatitis B Virus Core Antibody (HBcAb)
Hepatitis B Virus Surface Antibody (HBsAb)
Hepatitis B Virus Surface Antigen (HBsAg)
Hepatitis C Virus (HCV)</description>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Serology From Screening Visit and Study Termination Visit: Hepatitis A, Hepatitis B, and Hepatitis C</title>
          <description>Hepatitis A Virus Antibody (HAV Ab)
Hepatitis B Virus Core Antibody (HBcAb)
Hepatitis B Virus Surface Antibody (HBsAb)
Hepatitis B Virus Surface Antigen (HBsAg)
Hepatitis C Virus (HCV)</description>
          <population>Safety Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAV Ab: Screening Negative; Termination Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAV Ab: Screening Negative; Termination Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAV Ab: Screening Positive; Termination Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAV Ab: Screening Positive; Termination Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAV Ab: Serology not available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBcAb: Screening Negative; Termination Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBcAb: Screening Negative; Termination Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBcAb: Screening Positive; Termination Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBcAb: Screening Positive; Termination Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBcAb: Serology not available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAb: Screening Negative; Termination Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAb: Screening Negative; Termination Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAb: Screening Positive; Termination Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAb: Screening Positive; Termination Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAb: Serology not available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg: Screening Negative; Termination Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg: Screening Negative; Termination Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg: Serology not available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HCV: Screening Negative; Termination Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HCV: Screening Negative; Termination Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HCV: Screening Positive; Termination Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HCV: Screening Positive; Termination Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HCV: Serology not available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Serology From Screening Visit and Study Termination Visit: HIV-1/2 Antibody (Ab)</title>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated): FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Serology From Screening Visit and Study Termination Visit: HIV-1/2 Antibody (Ab)</title>
          <population>Safety Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HIV 1/2 Ab: Screen Negative; Termination Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV 1/2 Ab: Screen Negative; Termination Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV 1/2 Ab: : Serology not available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Serology From Screening Visit and Study Termination Visit: Parvovirus B19 IgG Antibody [IV]</title>
        <description>Normal range (0 - 0.89 IV); High (&gt; 0.89 IV)
- Parvovirus B19 IgG Antibody [IV] (Parvo IgG Ab)</description>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Serology From Screening Visit and Study Termination Visit: Parvovirus B19 IgG Antibody [IV]</title>
          <description>Normal range (0 - 0.89 IV); High (&gt; 0.89 IV)
- Parvovirus B19 IgG Antibody [IV] (Parvo IgG Ab)</description>
          <population>Safety Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Parvo IgG Ab: Screening High ; Termination Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parvo IgG Ab: Screening High ; Termination High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parvo IgG Ab: Screening Normal; Termination Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parvo IgG Ab: Screening Normal ; Termination High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parvo IgG Ab: Serology not available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Serology From Screening Visit and Study Termination Visit: Parvovirus B19 IgM Antibody [IV]</title>
        <description>Normal range (0 - 0.89 IV); High (&gt; 0.89 IV)
- Parvovirus B19 IgM Antibody [IV] (Parvo IgM Ab)</description>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Serology From Screening Visit and Study Termination Visit: Parvovirus B19 IgM Antibody [IV]</title>
          <description>Normal range (0 - 0.89 IV); High (&gt; 0.89 IV)
- Parvovirus B19 IgM Antibody [IV] (Parvo IgM Ab)</description>
          <population>Safety Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Parvo IgM Ab: Screening High ; Termination Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parvo IgM Ab: Screening High ; Termination High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parvo IgM Ab: Screening Normal; Termination Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parvo IgM Ab: Screening Normal ; Termination High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parvo IgM Ab: Serology not available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Related Adverse Events (AEs) Per Year</title>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Related Adverse Events (AEs) Per Year</title>
          <population>Safety Analysis Set</population>
          <units>Related AEs per year</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="0.000" upper_limit="0.000"/>
                    <measurement group_id="O2" value="0.000" lower_limit="0.000" upper_limit="0.979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Related Adverse Events (AEs) During or Within 1 Hour of Infusion Per Year</title>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Related Adverse Events (AEs) During or Within 1 Hour of Infusion Per Year</title>
          <population>Safety Analysis Set</population>
          <units>Related AEs within/during 1hr per year</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="0.000" upper_limit="0.000"/>
                    <measurement group_id="O2" value="0.000" lower_limit="0.000" upper_limit="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Related Thromboembolic Adverse Events (AEs)</title>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Related Thromboembolic Adverse Events (AEs)</title>
          <population>Safety Analysis Set</population>
          <units>Related thromboembolic AEs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Changes in Inhibitor Titer of Hemophilia A Participants With Shifts in Factor VIII (FVIII) Inhibitor Titer Levels</title>
        <description>Absolute Changes in Inhibitor Titer (or no change in low or high titer status):
Inhibitor Titer went from Low (≤5 BU) to Low (≤5 BU)
Inhibitor Titer went from Low (≤5 BU) to High (&gt;5 BU)
Inhibitor Titer went from High (&gt;5 BU) to Low (≤5 BU)
Inhibitor Titer went from High (&gt;5 BU) to High (&gt;5 BU)</description>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Safety Analysis Set
- Hemophilia A study participants</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Changes in Inhibitor Titer of Hemophilia A Participants With Shifts in Factor VIII (FVIII) Inhibitor Titer Levels</title>
          <description>Absolute Changes in Inhibitor Titer (or no change in low or high titer status):
Inhibitor Titer went from Low (≤5 BU) to Low (≤5 BU)
Inhibitor Titer went from Low (≤5 BU) to High (&gt;5 BU)
Inhibitor Titer went from High (&gt;5 BU) to Low (≤5 BU)
Inhibitor Titer went from High (&gt;5 BU) to High (&gt;5 BU)</description>
          <population>Safety Analysis Set
- Hemophilia A study participants</population>
          <units>Bethesda Units (BU)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening to 3 Month- Low to High (N=2, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" lower_limit="12.1" upper_limit="12.1"/>
                    <measurement group_id="O2" value="4.0" lower_limit="0.7" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening to 3 Month- High to Low (N=1, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="2" upper_limit="2"/>
                    <measurement group_id="O2" value="NA">There were no inhibitor titer shifts for this arm/group at this time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening to 6 Month- Low to High (N=2, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" lower_limit="4.9" upper_limit="20.8"/>
                    <measurement group_id="O2" value="5.3" lower_limit="5.3" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening to 6 Month- High to Low (N=1, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="3.4" upper_limit="3.4"/>
                    <measurement group_id="O2" value="NA">There were no inhibitor titer shifts for this arm/group at this time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening to 9 Month- Low to High (N=2, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="4.3" upper_limit="5.6"/>
                    <measurement group_id="O2" value="3.7" lower_limit="3.7" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening to 9 Month- High to Low (N=0, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There were no inhibitor titer shifts for this arm/group at this time point</measurement>
                    <measurement group_id="O2" value="2.1" lower_limit="0.9" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening to Termination- Low to High (N=2, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2" lower_limit="3.8" upper_limit="74.7"/>
                    <measurement group_id="O2" value="5.8" lower_limit="5.8" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening to Termination- High to Low (N=1, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="14.6" upper_limit="14.6"/>
                    <measurement group_id="O2" value="3.3" lower_limit="3.3" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Changes in Inhibitor Titer of Hemophilia B Participants With Shifts in Factor IX (FIX) Inhibitor Titer Levels</title>
        <description>Absolute Changes in Inhibitor Titer (or no change in low or high titer status):
Inhibitor Titer went from Low (≤5 BU) to Low (≤5 BU)
Inhibitor Titer went from Low (≤5 BU) to High (&gt;5 BU)
Inhibitor Titer went from High (&gt;5 BU) to Low (≤5 BU)
Inhibitor Titer went from High (&gt;5 BU) to High (&gt;5 BU)</description>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Safety Analysis Set
- Hemophilia B study participants</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated): FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Changes in Inhibitor Titer of Hemophilia B Participants With Shifts in Factor IX (FIX) Inhibitor Titer Levels</title>
          <description>Absolute Changes in Inhibitor Titer (or no change in low or high titer status):
Inhibitor Titer went from Low (≤5 BU) to Low (≤5 BU)
Inhibitor Titer went from Low (≤5 BU) to High (&gt;5 BU)
Inhibitor Titer went from High (&gt;5 BU) to Low (≤5 BU)
Inhibitor Titer went from High (&gt;5 BU) to High (&gt;5 BU)</description>
          <population>Safety Analysis Set
- Hemophilia B study participants</population>
          <units>Bethesda Units (BU)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening to 3 Month- Low to Low (N=1, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="3.2" upper_limit="3.2"/>
                    <measurement group_id="O2" value="NA">There were no inhibitor titer shifts for this arm/group at this time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening to 3 Month- Low to High (N=0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There were no inhibitor titer shifts for this arm/group at this time point</measurement>
                    <measurement group_id="O2" value="NA">There were no inhibitor titer shifts for this arm/group at this time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening to 3 Month- High to Low (N=0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There were no inhibitor titer shifts for this arm/group at this time point</measurement>
                    <measurement group_id="O2" value="NA">There were no inhibitor titer shifts for this arm/group at this time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening to 3 Month- High to High (N=1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                    <measurement group_id="O2" value="10.7" lower_limit="10.7" upper_limit="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening to 6 Month- Low to Low (N=1, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.5" upper_limit="1.5"/>
                    <measurement group_id="O2" value="NA">There were no inhibitor titer shifts for this arm/group at this time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening to 6 Month- Low to High (N=0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There were no inhibitor titer shifts for this arm/group at this time point</measurement>
                    <measurement group_id="O2" value="NA">There were no inhibitor titer shifts for this arm/group at this time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening to 6 Month- High to Low (N=0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There were no inhibitor titer shifts for this arm/group at this time point</measurement>
                    <measurement group_id="O2" value="NA">There were no inhibitor titer shifts for this arm/group at this time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening to 6 Month- High to High (N=1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.7" upper_limit="1.7"/>
                    <measurement group_id="O2" value="23.2" lower_limit="23.2" upper_limit="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening to 9 Month- Low to Low (N=1, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="3.2" upper_limit="3.2"/>
                    <measurement group_id="O2" value="NA">There were no inhibitor titer shifts for this arm/group at this time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening to 9 Month- Low to High (N=0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There were no inhibitor titer shifts for this arm/group at this time point</measurement>
                    <measurement group_id="O2" value="NA">There were no inhibitor titer shifts for this arm/group at this time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening to 9 Month- High to Low (N=0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There were no inhibitor titer shifts for this arm/group at this time point</measurement>
                    <measurement group_id="O2" value="NA">There were no inhibitor titer shifts for this arm/group at this time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening to 9 Month- High to High (N=0, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There were no inhibitor titer shifts for this arm/group at this time point</measurement>
                    <measurement group_id="O2" value="37.0" lower_limit="37.0" upper_limit="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening to Termination - Low to Low (N=0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There were no inhibitor titer shifts for this arm/group at this time point</measurement>
                    <measurement group_id="O2" value="NA">There were no inhibitor titer shifts for this arm/group at this time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening to Termination- Low to High (N=0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There were no inhibitor titer shifts for this arm/group at this time point</measurement>
                    <measurement group_id="O2" value="NA">There were no inhibitor titer shifts for this arm/group at this time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening to Termination- High to Low (N=0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There were no inhibitor titer shifts for this arm/group at this time point</measurement>
                    <measurement group_id="O2" value="NA">There were no inhibitor titer shifts for this arm/group at this time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening to Termination - High to High (N=1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" lower_limit="11.3" upper_limit="11.3"/>
                    <measurement group_id="O2" value="21.4" lower_limit="21.4" upper_limit="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacoeconomics: Annual Days Lost Due to Bleeding (Work or School)</title>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Intent to Treat Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacoeconomics: Annual Days Lost Due to Bleeding (Work or School)</title>
          <population>Intent to Treat Analysis Set</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" spread="25.76" lower_limit="0.0" upper_limit="20.0"/>
                    <measurement group_id="O2" value="8.8" spread="14.42" lower_limit="0.0" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacoeconomics: Annual Number of Hospitalizations for Bleeding</title>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Pharmacoeconomic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacoeconomics: Annual Number of Hospitalizations for Bleeding</title>
          <population>Pharmacoeconomic Analysis Set</population>
          <units>hospitalizations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.15" lower_limit="0.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.6" spread="2.03" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacoeconomics: Annual Number of Hospitalizations for Indwelling Line</title>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Pharmacoeconomic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacoeconomics: Annual Number of Hospitalizations for Indwelling Line</title>
          <population>Pharmacoeconomic Analysis Set</population>
          <units>hospitalizations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.32" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.1" spread="0.25" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacoeconomics: Annual Number of Emergency Room Visits</title>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Pharmacoeconomic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacoeconomics: Annual Number of Emergency Room Visits</title>
          <population>Pharmacoeconomic Analysis Set</population>
          <units>Emergency room visits</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.98" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.4" spread="1.09" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacoeconomics: Annual Number of Physician’s Office Visits</title>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Pharmacoeconomic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacoeconomics: Annual Number of Physician’s Office Visits</title>
          <population>Pharmacoeconomic Analysis Set</population>
          <units>Physician's office visits</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="4.15" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.6" spread="4.60" lower_limit="0.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacoeconomics: Annual Total Length of Hospitalization for Bleeding</title>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Pharmacoeconomic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacoeconomics: Annual Total Length of Hospitalization for Bleeding</title>
          <population>Pharmacoeconomic Analysis Set</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="9.48" lower_limit="0.0" upper_limit="9.0"/>
                    <measurement group_id="O2" value="5.3" spread="17.00" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacoeconomics: Annual Total Length of Hospitalization for Indwelling Line</title>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Pharmacoeconomic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacoeconomics: Annual Total Length of Hospitalization for Indwelling Line</title>
          <population>Pharmacoeconomic Analysis Set</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="2.61"/>
                    <measurement group_id="O2" value="0.7" spread="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacoeconomics: Annual Total Number of Days Lost (Work or School)</title>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Pharmacoeconomic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacoeconomics: Annual Total Number of Days Lost (Work or School)</title>
          <population>Pharmacoeconomic Analysis Set</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" spread="25.42"/>
                    <measurement group_id="O2" value="15.4" spread="24.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-Related Quality of Life (HRQoL): EuroQoL (Quality of Life)-5 Dimensions (EQ-5D) Index Scores</title>
        <description>EQ-5D is a participant answered questionnaire scoring 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome.
EQ-5D Index scores based on EQ-5D questionnaire were calculated for participants ≥14 years of age, at screening, 6 months, and at termination visit. Changes in scores at 6 months and termination were also calculated.
A relatively higher score represents better quality of life.</description>
        <time_frame>12 months ± 14 days</time_frame>
        <population>HRQoL Intent-to-Treat Analysis Dataset - comprised of all participants ≥14 years of age who were randomized, had any available assessments at any available study visits (baseline, 6- month, and 12-month) as defined in the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Health-Related Quality of Life (HRQoL): EuroQoL (Quality of Life)-5 Dimensions (EQ-5D) Index Scores</title>
          <description>EQ-5D is a participant answered questionnaire scoring 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome.
EQ-5D Index scores based on EQ-5D questionnaire were calculated for participants ≥14 years of age, at screening, 6 months, and at termination visit. Changes in scores at 6 months and termination were also calculated.
A relatively higher score represents better quality of life.</description>
          <population>HRQoL Intent-to-Treat Analysis Dataset - comprised of all participants ≥14 years of age who were randomized, had any available assessments at any available study visits (baseline, 6- month, and 12-month) as defined in the protocol</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening (N= 16, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.627" spread="0.2067"/>
                    <measurement group_id="O2" value="0.620" spread="0.1841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months (N= 15, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.621" spread="0.1880"/>
                    <measurement group_id="O2" value="0.729" spread="0.1392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Termination (N= 15, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.605" spread="0.2146"/>
                    <measurement group_id="O2" value="0.700" spread="0.1233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change (Screening - Month 6) (N= 15, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.006" spread="0.2088"/>
                    <measurement group_id="O2" value="-0.096" spread="0.2403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change (Screening - Termination) (N= 15, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010" spread="0.2470"/>
                    <measurement group_id="O2" value="-0.075" spread="0.2594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change (Month 6 - Termination) (N= 15, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.016" spread="0.1765"/>
                    <measurement group_id="O2" value="0.001" spread="0.1493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemophilia-specific Quality of Life Questionnaire for Adults (Haem-A-QoL) ≥ 16 Years Old</title>
        <description>The Haem-A-QoL instrument has been developed and used in Hemophilia A patients. As a hemophilia-specific instrument, this measure assesses very specific aspects of dealing with hemophilia. The areas covered by this instrument are: Physical Health (PH), Sports &amp; Leisure (S&amp;L), School &amp; Work (W&amp;S), Dealing with Hemophilia (Dealing), Family Planning (FP), Feeling, Relationships (R'ships), Treatment, View, and Outlook for the Future (Future). A Haem-A-QoL Total Score (Total) was also calculated. For the Haem-A-QoL, higher scores indicate a worse quality of life. Scores on a scale range between 0 and 100.
Haem-A-QoL scores at screening, 6 months, and at termination visit were collected. Changes in scores at 6 months and termination were also calculated.</description>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Health-Related Quality of Life (HRQoL) Intent-to-Treat Analysis Dataset for all participants ≥ 16 years old who were randomized, had any available assessments at any available study visits (baseline, 6-month, and 12-month) as defined in the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Hemophilia-specific Quality of Life Questionnaire for Adults (Haem-A-QoL) ≥ 16 Years Old</title>
          <description>The Haem-A-QoL instrument has been developed and used in Hemophilia A patients. As a hemophilia-specific instrument, this measure assesses very specific aspects of dealing with hemophilia. The areas covered by this instrument are: Physical Health (PH), Sports &amp; Leisure (S&amp;L), School &amp; Work (W&amp;S), Dealing with Hemophilia (Dealing), Family Planning (FP), Feeling, Relationships (R'ships), Treatment, View, and Outlook for the Future (Future). A Haem-A-QoL Total Score (Total) was also calculated. For the Haem-A-QoL, higher scores indicate a worse quality of life. Scores on a scale range between 0 and 100.
Haem-A-QoL scores at screening, 6 months, and at termination visit were collected. Changes in scores at 6 months and termination were also calculated.</description>
          <population>Health-Related Quality of Life (HRQoL) Intent-to-Treat Analysis Dataset for all participants ≥ 16 years old who were randomized, had any available assessments at any available study visits (baseline, 6-month, and 12-month) as defined in the protocol</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dealing- Screening (N=15, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" spread="19.72"/>
                    <measurement group_id="O2" value="26.0" spread="15.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dealing- Month 6 (N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="16.67"/>
                    <measurement group_id="O2" value="18.9" spread="21.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dealing- Termination (N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" spread="25.21"/>
                    <measurement group_id="O2" value="23.7" spread="22.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dealing- Change (Screening - Month 6) (N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="18.61"/>
                    <measurement group_id="O2" value="3.4" spread="22.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dealing- Change(Screening - Termination)(N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="27.19"/>
                    <measurement group_id="O2" value="-1.4" spread="21.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dealing- Change (Month 6 - Termination)(N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="16.81"/>
                    <measurement group_id="O2" value="-4.8" spread="21.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FP- Screening (N=9, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="20.49"/>
                    <measurement group_id="O2" value="34.9" spread="31.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FP- Month 6 (N=12, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" spread="26.71"/>
                    <measurement group_id="O2" value="14.3" spread="11.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FP- Termination (N=13, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1" spread="16.25"/>
                    <measurement group_id="O2" value="21.1" spread="22.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FP- Change (Screening - Month 6) (N=9, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="26.94"/>
                    <measurement group_id="O2" value="14.9" spread="28.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FP- Change(Screening - Termination)(N=9, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="25.57"/>
                    <measurement group_id="O2" value="13.1" spread="20.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FP- Change (Month 6 - Termination)(N=11, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="32.68"/>
                    <measurement group_id="O2" value="-8.3" spread="28.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling- Screening (N=15, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6" spread="28.22"/>
                    <measurement group_id="O2" value="48.2" spread="29.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling- Month 6 (N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9" spread="28.77"/>
                    <measurement group_id="O2" value="29.0" spread="17.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling- Termination (N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8" spread="28.53"/>
                    <measurement group_id="O2" value="26.1" spread="20.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling- Change (Screening - Month 6) (N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="27.75"/>
                    <measurement group_id="O2" value="17.3" spread="34.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling- Change(Screening - Termination)(N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="31.91"/>
                    <measurement group_id="O2" value="20.2" spread="24.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling- Change (Month 6 - Termination)(N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="16.40"/>
                    <measurement group_id="O2" value="2.8" spread="23.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Future- Screening (N=14, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.8" spread="28.46"/>
                    <measurement group_id="O2" value="48.6" spread="23.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Future- Month 6 (N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.2" spread="26.14"/>
                    <measurement group_id="O2" value="46.0" spread="18.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Future- Termination (N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9" spread="25.47"/>
                    <measurement group_id="O2" value="46.8" spread="18.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Future- Change (Screening - Month 6) (N=13, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="26.84"/>
                    <measurement group_id="O2" value="1.1" spread="24.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Future- Change(Screening - Termination)(N=13, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="20.53"/>
                    <measurement group_id="O2" value="0.3" spread="16.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Future- Change (Month 6 - Termination)(N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.7" spread="20.25"/>
                    <measurement group_id="O2" value="-0.8" spread="16.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PH- Screening (N=15, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.0" spread="22.46"/>
                    <measurement group_id="O2" value="66.4" spread="24.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PH- Month 6 (N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" spread="27.55"/>
                    <measurement group_id="O2" value="43.1" spread="25.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PH- Termination (N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1" spread="24.98"/>
                    <measurement group_id="O2" value="42.3" spread="18.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PH- Change (Screening - Month 6) (N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" spread="21.70"/>
                    <measurement group_id="O2" value="21.1" spread="28.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PH- Change(Screening - Termination)(N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="23.93"/>
                    <measurement group_id="O2" value="21.9" spread="24.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PH- Change (Month 6 - Termination)(N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="10.65"/>
                    <measurement group_id="O2" value="0.8" spread="20.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R'ships- Screening (N=15, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3" spread="36.57"/>
                    <measurement group_id="O2" value="26.9" spread="28.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R'ships- Month 6 (N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" spread="28.20"/>
                    <measurement group_id="O2" value="15.2" spread="13.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R'ships- Termination (N=14, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" spread="22.13"/>
                    <measurement group_id="O2" value="15.0" spread="17.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R'ships- Change (Screening - Month 6) (N=14, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="34.04"/>
                    <measurement group_id="O2" value="10.4" spread="27.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R'ships- Change(Screening - Termination)(N=14, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="30.57"/>
                    <measurement group_id="O2" value="12.1" spread="25.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R'ships- Change (Month 6 - Termination)(N=14, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="21.40"/>
                    <measurement group_id="O2" value="1.7" spread="16.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S&amp;L- Screening (N=12, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.3" spread="17.11"/>
                    <measurement group_id="O2" value="83.1" spread="14.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S&amp;L- Month 6 (N=12, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.1" spread="23.09"/>
                    <measurement group_id="O2" value="69.7" spread="19.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S&amp;L- Termination (N=12, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.3" spread="17.30"/>
                    <measurement group_id="O2" value="78.1" spread="12.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S&amp;L- Change (Screening - Month 6) (N=9, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" spread="19.75"/>
                    <measurement group_id="O2" value="20.5" spread="27.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S&amp;L- Change(Screening - Termination)(N=9, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="15.91"/>
                    <measurement group_id="O2" value="7.0" spread="21.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S&amp;L- Change (Month 6 - Termination)(N=11, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.2" spread="13.44"/>
                    <measurement group_id="O2" value="-2.5" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment- Screening (N=15, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9" spread="13.32"/>
                    <measurement group_id="O2" value="39.6" spread="20.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment- Month 6 (N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4" spread="19.82"/>
                    <measurement group_id="O2" value="40.9" spread="16.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment- Termination (N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8" spread="14.87"/>
                    <measurement group_id="O2" value="42.6" spread="17.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment- Change (Screening - Month 6) (N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="23.72"/>
                    <measurement group_id="O2" value="0.0" spread="16.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-Change(Screening -Termination)(N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="17.81"/>
                    <measurement group_id="O2" value="-1.7" spread="23.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment- Change (Month 6- Termination)(N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="15.07"/>
                    <measurement group_id="O2" value="-1.7" spread="18.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>View- Screening (N=15, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3" spread="24.49"/>
                    <measurement group_id="O2" value="55.6" spread="11.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>View- Month 6 (N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3" spread="27.66"/>
                    <measurement group_id="O2" value="40.0" spread="13.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>View- Termination (N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9" spread="22.59"/>
                    <measurement group_id="O2" value="37.7" spread="21.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>View- Change (Screening - Month 6) (N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="23.68"/>
                    <measurement group_id="O2" value="14.3" spread="17.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>View- Change (Screening -Termination)(N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="23.79"/>
                    <measurement group_id="O2" value="16.6" spread="15.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>View- Change (Month 6- Termination)(N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="17.03"/>
                    <measurement group_id="O2" value="2.3" spread="20.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W&amp;S-Screening (N=13, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8" spread="25.90"/>
                    <measurement group_id="O2" value="57.7" spread="17.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W&amp;S- Month 6 (N=13, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7" spread="26.82"/>
                    <measurement group_id="O2" value="37.5" spread="20.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W&amp;S- Termination (N=12, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" spread="22.53"/>
                    <measurement group_id="O2" value="36.8" spread="19.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W&amp;S- Change (Screening - Month 6) (N=12, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="30.98"/>
                    <measurement group_id="O2" value="25.3" spread="25.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W&amp;S- Change (Screening -Termination)(N=12, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" spread="33.86"/>
                    <measurement group_id="O2" value="25.3" spread="19.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>W&amp;S- Change (Month 6- Termination)(N=12, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="15.95"/>
                    <measurement group_id="O2" value="0.7" spread="21.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total- Screening (N=14, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0" spread="15.50"/>
                    <measurement group_id="O2" value="49.2" spread="15.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total- Month 6 (N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.4" spread="19.37"/>
                    <measurement group_id="O2" value="38.1" spread="11.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total- Termination (N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.2" spread="17.55"/>
                    <measurement group_id="O2" value="38.7" spread="14.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total- Change (Screening - Month 6) (N=13, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" spread="18.44"/>
                    <measurement group_id="O2" value="10.2" spread="17.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total- Change (Screening -Termination)(N=13, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="15.41"/>
                    <measurement group_id="O2" value="9.5" spread="12.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total- Change (Month 6- Termination)(N=14, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="9.21"/>
                    <measurement group_id="O2" value="-0.7" spread="14.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemophilia-specific Quality of Life Questionnaire for Children and Adolescents &lt; 16 Years Old (Haemo-QoL) - Parent's Evaluation</title>
        <description>The Haemo-QoL is a quality of life (QoL) assessment instrument for children and adolescents with haemophilia. As a hemophilia-specific instrument, this measure assesses very specific aspects of dealing with hemophilia. The areas covered by this instrument are: Physical Health (PH), Sports &amp; School (S&amp;S), Dealing with Hemophilia (Dealing), Family, Feeling, Relationships (R'ships), Treatment, View, Outlook for the Future (Future), Friends, Others, and Support. A Haemo-QoL Total Score (Total) was also calculated. For the Haemo-QoL, higher scores indicate a worse quality of life. Scores on a scale range between 0 and 100.
Haemo-QoL scores at screening, 6 months, and at termination visit were collected. Changes in scores at 6 months and termination were also calculated.</description>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Health-Related Quality of Life (HRQoL) Intent-to-Treat Analysis Dataset - for all participants &lt;16 years old who were randomized, had any available assessments at any available study visits (baseline, 6-month, and 12-month) as defined in the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Hemophilia-specific Quality of Life Questionnaire for Children and Adolescents &lt; 16 Years Old (Haemo-QoL) - Parent's Evaluation</title>
          <description>The Haemo-QoL is a quality of life (QoL) assessment instrument for children and adolescents with haemophilia. As a hemophilia-specific instrument, this measure assesses very specific aspects of dealing with hemophilia. The areas covered by this instrument are: Physical Health (PH), Sports &amp; School (S&amp;S), Dealing with Hemophilia (Dealing), Family, Feeling, Relationships (R'ships), Treatment, View, Outlook for the Future (Future), Friends, Others, and Support. A Haemo-QoL Total Score (Total) was also calculated. For the Haemo-QoL, higher scores indicate a worse quality of life. Scores on a scale range between 0 and 100.
Haemo-QoL scores at screening, 6 months, and at termination visit were collected. Changes in scores at 6 months and termination were also calculated.</description>
          <population>Health-Related Quality of Life (HRQoL) Intent-to-Treat Analysis Dataset - for all participants &lt;16 years old who were randomized, had any available assessments at any available study visits (baseline, 6-month, and 12-month) as defined in the protocol</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dealing- Screening (N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9" spread="11.80"/>
                    <measurement group_id="O2" value="39.3" spread="17.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dealing- Month 6 (N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" spread="19.31"/>
                    <measurement group_id="O2" value="36.6" spread="16.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dealing- Termination (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" spread="16.24"/>
                    <measurement group_id="O2" value="28.6" spread="13.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dealing- Change (Screening - Month 6) (N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="8.61"/>
                    <measurement group_id="O2" value="2.7" spread="7.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dealing- Change(Screening - Termination)(N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="7.92"/>
                    <measurement group_id="O2" value="13.4" spread="5.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dealing- Change (Month 6 - Termination)(N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="11.85"/>
                    <measurement group_id="O2" value="10.7" spread="7.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family- Screening (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3" spread="19.05"/>
                    <measurement group_id="O2" value="50.9" spread="8.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family- Month 6 (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.3" spread="27.65"/>
                    <measurement group_id="O2" value="49.1" spread="10.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family- Termination (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8" spread="31.03"/>
                    <measurement group_id="O2" value="39.8" spread="13.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family- Change (Screening - Month 6) (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="9.26"/>
                    <measurement group_id="O2" value="1.7" spread="15.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family- Change(Screening - Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="15.52"/>
                    <measurement group_id="O2" value="11.1" spread="19.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family- Change (Month 6 - Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="12.16"/>
                    <measurement group_id="O2" value="9.3" spread="5.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling- Screening (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1" spread="14.25"/>
                    <measurement group_id="O2" value="38.2" spread="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling- Month 6 (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.3" spread="27.02"/>
                    <measurement group_id="O2" value="37.5" spread="22.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling- Termination (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" spread="36.07"/>
                    <measurement group_id="O2" value="27.8" spread="16.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling- Change (Screening - Month 6) (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="24.27"/>
                    <measurement group_id="O2" value="0.7" spread="24.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling- Change(Screening - Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="27.92"/>
                    <measurement group_id="O2" value="10.5" spread="19.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling- Change (Month 6 - Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="13.85"/>
                    <measurement group_id="O2" value="9.7" spread="20.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Friends- Screening (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.9" spread="20.65"/>
                    <measurement group_id="O2" value="52.1" spread="17.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Friends- Month 6 (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" spread="17.95"/>
                    <measurement group_id="O2" value="36.3" spread="29.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Friends- Termination (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4" spread="14.88"/>
                    <measurement group_id="O2" value="66.3" spread="20.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Friends- Change (Screening - Month 6) (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="27.72"/>
                    <measurement group_id="O2" value="15.8" spread="21.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Friends- Change(Screening - Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="17.95"/>
                    <measurement group_id="O2" value="-14.2" spread="28.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Friends- Change (Month 6 - Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="22.46"/>
                    <measurement group_id="O2" value="-30.0" spread="31.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Future- Screening (N=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.1" spread="13.26"/>
                    <measurement group_id="O2" value="43.8" spread="17.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Future- Month 6 (N=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.6" spread="13.26"/>
                    <measurement group_id="O2" value="37.5" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Future- Termination (N=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3" spread="0.00"/>
                    <measurement group_id="O2" value="43.8" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Future- Change (Screening - Month 6) (N=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="0.00"/>
                    <measurement group_id="O2" value="6.3" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Future- Change(Screening - Termination)(N=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" spread="13.26"/>
                    <measurement group_id="O2" value="0.0" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Future- Change (Month 6 - Termination)(N=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="13.26"/>
                    <measurement group_id="O2" value="-6.3" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others- Screening (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" spread="34.44"/>
                    <measurement group_id="O2" value="29.2" spread="16.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others- Month 6 (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7" spread="39.14"/>
                    <measurement group_id="O2" value="24.2" spread="15.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others- Termination (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" spread="32.87"/>
                    <measurement group_id="O2" value="25.8" spread="13.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others- Change (Screening - Month 6) (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.6" spread="16.80"/>
                    <measurement group_id="O2" value="5.0" spread="20.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others- Change(Screening - Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="15.36"/>
                    <measurement group_id="O2" value="3.3" spread="15.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others- Change (Month 6 - Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" spread="19.98"/>
                    <measurement group_id="O2" value="-1.7" spread="10.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PH- Screening (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.0" spread="11.06"/>
                    <measurement group_id="O2" value="52.1" spread="23.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PH- Month 6 (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.6" spread="13.98"/>
                    <measurement group_id="O2" value="48.0" spread="17.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PH- Termination (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1" spread="11.85"/>
                    <measurement group_id="O2" value="40.4" spread="17.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PH- Change (Screening - Month 6) (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="12.16"/>
                    <measurement group_id="O2" value="4.1" spread="32.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PH- Change(Screening - Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" spread="17.10"/>
                    <measurement group_id="O2" value="11.8" spread="29.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PH- Change (Month 6 - Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="22.87"/>
                    <measurement group_id="O2" value="7.7" spread="22.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R'ships- Screening (N=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="17.68"/>
                    <measurement group_id="O2" value="43.8" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R'ships- Month 6 (N=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="35.36"/>
                    <measurement group_id="O2" value="43.8" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R'ships- Termination (N=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="37.5" spread="17.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R'ships- Change (Screening - Month 6) (N=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.5" spread="17.68"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R'ships-Change(Screening -Termination)(N=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="17.68"/>
                    <measurement group_id="O2" value="6.3" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R'ships- Change (Month 6- Termination)(N=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="35.36"/>
                    <measurement group_id="O2" value="6.3" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S&amp;S- Screening (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.1" spread="10.68"/>
                    <measurement group_id="O2" value="59.1" spread="23.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S&amp;S- Month 6 (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" spread="7.74"/>
                    <measurement group_id="O2" value="56.5" spread="9.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S&amp;S- Termination (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" spread="17.16"/>
                    <measurement group_id="O2" value="57.2" spread="17.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S&amp;S- Change (Screening - Month 6) (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="6.89"/>
                    <measurement group_id="O2" value="2.6" spread="16.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S&amp;S- Change (Screening -Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="12.02"/>
                    <measurement group_id="O2" value="1.9" spread="10.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S&amp;S- Change (Month 6- Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="18.07"/>
                    <measurement group_id="O2" value="-0.8" spread="8.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Support-Screening (N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" spread="25.77"/>
                    <measurement group_id="O2" value="51.6" spread="9.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Support-Month 6 (N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" spread="29.32"/>
                    <measurement group_id="O2" value="42.2" spread="17.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Support- Termination (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8" spread="32.02"/>
                    <measurement group_id="O2" value="48.8" spread="20.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Support- Change (Screening - Month 6) (N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="24.21"/>
                    <measurement group_id="O2" value="9.4" spread="10.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Support- Change (Screening -Termination)(N=4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="13.86"/>
                    <measurement group_id="O2" value="3.1" spread="15.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Support- Change (Month 6- Termination)(N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.1" spread="21.27"/>
                    <measurement group_id="O2" value="-6.3" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment- Screening (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0" spread="13.23"/>
                    <measurement group_id="O2" value="64.2" spread="22.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment- Month 6 (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" spread="6.90"/>
                    <measurement group_id="O2" value="54.8" spread="14.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment- Termination (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" spread="22.12"/>
                    <measurement group_id="O2" value="41.0" spread="13.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment- Change (Screening - Month 6) (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="10.10"/>
                    <measurement group_id="O2" value="9.4" spread="13.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment- Change(Screening -Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="17.16"/>
                    <measurement group_id="O2" value="23.2" spread="16.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment- Change (Month 6- Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="22.47"/>
                    <measurement group_id="O2" value="13.8" spread="11.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>View-Screening (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" spread="18.25"/>
                    <measurement group_id="O2" value="36.7" spread="16.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>View-Month 6 (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.3" spread="24.45"/>
                    <measurement group_id="O2" value="36.4" spread="22.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>View- Termination (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8" spread="35.68"/>
                    <measurement group_id="O2" value="30.8" spread="12.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>View- Change (Screening - Month 6) (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="6.38"/>
                    <measurement group_id="O2" value="0.3" spread="7.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>View- Change (Screening -Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" spread="18.62"/>
                    <measurement group_id="O2" value="5.9" spread="10.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>View- Change (Month 6- Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="13.02"/>
                    <measurement group_id="O2" value="5.6" spread="16.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total-Screening (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.7" spread="13.67"/>
                    <measurement group_id="O2" value="48.1" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total-Month 6 (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0" spread="13.84"/>
                    <measurement group_id="O2" value="42.3" spread="11.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total- Termination (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5" spread="21.83"/>
                    <measurement group_id="O2" value="39.5" spread="8.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total- Change (Screening - Month 6) (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.19"/>
                    <measurement group_id="O2" value="5.7" spread="14.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total- Change (Screening -Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="8.57"/>
                    <measurement group_id="O2" value="8.6" spread="8.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total- Change (Month 6- Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="8.91"/>
                    <measurement group_id="O2" value="2.8" spread="7.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemophilia-specific Quality of Life Questionnaire for Children and Adolescents &lt; 16 Years Old (Haemo-QoL) - Child's Evaluation</title>
        <description>The Haemo-QoL is a quality of life (QoL) assessment instrument for children and adolescents with haemophilia. As a hemophilia-specific instrument, this measure assesses very specific aspects of dealing with hemophilia. The areas covered by this instrument are: Physical Health (PH), Sports &amp; School (S&amp;S), Dealing with Hemophilia (Dealing), Family, Feeling, Relationships (R'ships), Treatment, View, Outlook for the Future (Future), Friends, Others, and Support. A Haemo-QoL Total Score (Total) was also calculated. For the Haemo-QoL, higher scores indicate a worse quality of life. Scores on a scale range between 0 and 100.
Haemo-QoL scores at screening, 6 months, and at termination visit were collected. Changes in scores at 6 months and termination were also calculated.</description>
        <time_frame>12 months ± 14 days</time_frame>
        <population>Health-Related Quality of Life (HRQoL) Intent-to-Treat Analysis Dataset - comprised of all participants &lt;16 years old, had any available assessments at any available study visits (baseline, 6-month, and 12-month) as defined in the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Hemophilia-specific Quality of Life Questionnaire for Children and Adolescents &lt; 16 Years Old (Haemo-QoL) - Child's Evaluation</title>
          <description>The Haemo-QoL is a quality of life (QoL) assessment instrument for children and adolescents with haemophilia. As a hemophilia-specific instrument, this measure assesses very specific aspects of dealing with hemophilia. The areas covered by this instrument are: Physical Health (PH), Sports &amp; School (S&amp;S), Dealing with Hemophilia (Dealing), Family, Feeling, Relationships (R'ships), Treatment, View, Outlook for the Future (Future), Friends, Others, and Support. A Haemo-QoL Total Score (Total) was also calculated. For the Haemo-QoL, higher scores indicate a worse quality of life. Scores on a scale range between 0 and 100.
Haemo-QoL scores at screening, 6 months, and at termination visit were collected. Changes in scores at 6 months and termination were also calculated.</description>
          <population>Health-Related Quality of Life (HRQoL) Intent-to-Treat Analysis Dataset - comprised of all participants &lt;16 years old, had any available assessments at any available study visits (baseline, 6-month, and 12-month) as defined in the protocol</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dealing- Screening (N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0" spread="17.10"/>
                    <measurement group_id="O2" value="44.6" spread="20.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dealing- Month 6 (N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" spread="2.92"/>
                    <measurement group_id="O2" value="37.5" spread="13.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dealing- Termination (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="9.22"/>
                    <measurement group_id="O2" value="32.9" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dealing- Change (Screening - Month 6) (N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="15.26"/>
                    <measurement group_id="O2" value="7.1" spread="8.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dealing- Change(Screening - Termination)(N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="15.26"/>
                    <measurement group_id="O2" value="14.3" spread="12.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dealing- Change (Month 6 - Termination)(N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="6.52"/>
                    <measurement group_id="O2" value="7.1" spread="6.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family- Screening (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5" spread="23.94"/>
                    <measurement group_id="O2" value="35.6" spread="22.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family- Month 6 (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.4" spread="28.78"/>
                    <measurement group_id="O2" value="36.4" spread="23.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family- Termination (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3" spread="21.25"/>
                    <measurement group_id="O2" value="32.5" spread="21.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family- Change (Screening - Month 6) (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="20.31"/>
                    <measurement group_id="O2" value="-0.7" spread="16.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family- Change(Screening - Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="25.72"/>
                    <measurement group_id="O2" value="3.1" spread="15.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family- Change (Month 6 - Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="13.66"/>
                    <measurement group_id="O2" value="3.9" spread="12.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling- Screening (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.8" spread="31.91"/>
                    <measurement group_id="O2" value="34.9" spread="12.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling- Month 6 (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4" spread="43.03"/>
                    <measurement group_id="O2" value="22.0" spread="18.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling- Termination (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4" spread="39.48"/>
                    <measurement group_id="O2" value="19.2" spread="15.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling- Change (Screening - Month 6) (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="16.91"/>
                    <measurement group_id="O2" value="12.9" spread="27.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling- Change(Screening - Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.4" spread="11.77"/>
                    <measurement group_id="O2" value="15.7" spread="23.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling- Change (Month 6 - Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="7.79"/>
                    <measurement group_id="O2" value="2.8" spread="15.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Friends- Screening (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4" spread="25.26"/>
                    <measurement group_id="O2" value="58.8" spread="20.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Friends- Month 6 (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" spread="15.73"/>
                    <measurement group_id="O2" value="42.5" spread="29.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Friends- Termination (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8" spread="12.88"/>
                    <measurement group_id="O2" value="56.3" spread="27.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Friends- Change (Screening - Month 6) (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="25.52"/>
                    <measurement group_id="O2" value="16.3" spread="24.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Friends- Change(Screening - Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="28.58"/>
                    <measurement group_id="O2" value="2.5" spread="22.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Friends- Change (Month 6 - Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="17.95"/>
                    <measurement group_id="O2" value="-13.8" spread="20.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Future- Screening (N=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.6" spread="13.26"/>
                    <measurement group_id="O2" value="43.8" spread="17.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Future- Month 6 (N=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8" spread="17.68"/>
                    <measurement group_id="O2" value="43.8" spread="17.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Future- Termination (N=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9" spread="22.10"/>
                    <measurement group_id="O2" value="28.1" spread="22.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Future- Change (Screening - Month 6) (N=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="4.42"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Future- Change(Screening - Termination)(N=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="8.84"/>
                    <measurement group_id="O2" value="15.6" spread="4.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Future- Change (Month 6 - Termination)(N=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="4.42"/>
                    <measurement group_id="O2" value="15.6" spread="4.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others- Screening (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7" spread="33.74"/>
                    <measurement group_id="O2" value="26.7" spread="20.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others- Month 6 (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" spread="40.11"/>
                    <measurement group_id="O2" value="16.7" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others- Termination (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" spread="21.11"/>
                    <measurement group_id="O2" value="13.3" spread="12.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others- Change (Screening - Month 6) (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="8.59"/>
                    <measurement group_id="O2" value="10.0" spread="25.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others- Change(Screening - Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="14.18"/>
                    <measurement group_id="O2" value="13.3" spread="23.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others- Change (Month 6 - Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" spread="19.39"/>
                    <measurement group_id="O2" value="3.3" spread="16.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PH- Screening (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.0" spread="24.98"/>
                    <measurement group_id="O2" value="42.1" spread="32.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PH- Month 6 (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.1" spread="14.69"/>
                    <measurement group_id="O2" value="33.9" spread="16.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PH- Termination (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1" spread="23.05"/>
                    <measurement group_id="O2" value="25.7" spread="10.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PH- Change (Screening - Month 6) (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" spread="19.56"/>
                    <measurement group_id="O2" value="8.2" spread="34.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PH- Change(Screening - Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9" spread="14.40"/>
                    <measurement group_id="O2" value="16.4" spread="29.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PH- Change (Month 6 - Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="12.16"/>
                    <measurement group_id="O2" value="8.2" spread="20.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R'ships- Screening (N=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="8.84"/>
                    <measurement group_id="O2" value="43.8" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R'ships- Month 6 (N=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" spread="26.52"/>
                    <measurement group_id="O2" value="43.8" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R'ships- Termination (N=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="8.84"/>
                    <measurement group_id="O2" value="18.8" spread="26.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R'ships- Change (Screening - Month 6) (N=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.5" spread="17.68"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R'ships-Change(Screening -Termination)(N=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="25.0" spread="17.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R'ships- Change (Month 6- Termination)(N=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="17.68"/>
                    <measurement group_id="O2" value="25.0" spread="17.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S&amp;S- Screening (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3" spread="14.74"/>
                    <measurement group_id="O2" value="51.3" spread="19.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S&amp;S- Month 6 (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.8" spread="13.42"/>
                    <measurement group_id="O2" value="54.2" spread="5.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S&amp;S- Termination (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.2" spread="5.64"/>
                    <measurement group_id="O2" value="49.8" spread="18.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S&amp;S- Change (Screening - Month 6) (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="11.42"/>
                    <measurement group_id="O2" value="-2.8" spread="18.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S&amp;S- Change (Screening -Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" spread="14.74"/>
                    <measurement group_id="O2" value="1.5" spread="18.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S&amp;S- Change (Month 6- Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="9.10"/>
                    <measurement group_id="O2" value="4.4" spread="15.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Support-Screening (N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8" spread="3.13"/>
                    <measurement group_id="O2" value="62.5" spread="31.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Support-Month 6 (N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" spread="10.83"/>
                    <measurement group_id="O2" value="56.3" spread="31.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Support- Termination (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" spread="17.21"/>
                    <measurement group_id="O2" value="65.0" spread="15.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Support- Change (Screening - Month 6) (N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="12.88"/>
                    <measurement group_id="O2" value="6.3" spread="31.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Support- Change (Screening -Termination)(N=4, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="18.75"/>
                    <measurement group_id="O2" value="-3.1" spread="18.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Support- Change (Month 6- Termination)(N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="10.67"/>
                    <measurement group_id="O2" value="-9.4" spread="25.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment- Screening (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" spread="15.38"/>
                    <measurement group_id="O2" value="69.6" spread="25.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment- Month 6 (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.6" spread="16.50"/>
                    <measurement group_id="O2" value="56.8" spread="15.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment- Termination (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.9" spread="26.10"/>
                    <measurement group_id="O2" value="44.2" spread="27.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment- Change (Screening - Month 6) (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="4.43"/>
                    <measurement group_id="O2" value="12.9" spread="21.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment- Change(Screening -Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="13.86"/>
                    <measurement group_id="O2" value="25.4" spread="28.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment- Change (Month 6- Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="11.25"/>
                    <measurement group_id="O2" value="12.6" spread="15.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>View-Screening (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0" spread="19.33"/>
                    <measurement group_id="O2" value="31.9" spread="14.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>View-Month 6 (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3" spread="33.02"/>
                    <measurement group_id="O2" value="32.4" spread="19.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>View- Termination (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5" spread="32.75"/>
                    <measurement group_id="O2" value="32.2" spread="8.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>View- Change (Screening - Month 6) (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="14.96"/>
                    <measurement group_id="O2" value="-0.5" spread="18.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>View- Change (Screening -Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="16.56"/>
                    <measurement group_id="O2" value="-0.3" spread="10.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>View- Change (Month 6- Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="8.67"/>
                    <measurement group_id="O2" value="0.2" spread="13.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total-Screening (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.9" spread="12.28"/>
                    <measurement group_id="O2" value="45.1" spread="9.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total-Month 6 (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.4" spread="17.91"/>
                    <measurement group_id="O2" value="37.7" spread="9.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total- Termination (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2" spread="17.96"/>
                    <measurement group_id="O2" value="35.3" spread="9.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total- Change (Screening - Month 6) (N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="7.21"/>
                    <measurement group_id="O2" value="7.4" spread="16.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total- Change (Screening -Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="8.69"/>
                    <measurement group_id="O2" value="9.8" spread="12.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total- Change (Month 6- Termination)(N=4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="3.55"/>
                    <measurement group_id="O2" value="2.5" spread="9.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-Related Quality of Life (HRQoL) - General Pain Assessment Using a Visual Analogue Scale (VAS) in Adults and Adolescents ≥12 Years Old</title>
        <description>General pain was assessed using a VAS pain scale at screening, 6 months, and at termination. Unlike the VAS pain assessment for pain of bleeding episodes (Outcome above), this general pain assessment did not take use of analgesics into account. For the pain scale, a higher number indicates worse pain.
The visual analog scale ranges from 0 to 100 where the endpoints are labeled 'Worst imaginable health state' (=0) and 'Best imaginable health state' (=100). A positive change from baseline indicates improvement.
Change in VAS scores at 6 months and study termination were also compared relative to Baseline/Screening scores (ie, (Baseline/Screening VAS score) - (VAS score at 6 months and study termination).</description>
        <time_frame>Baseline, 6 months and 12 months ± 14 days</time_frame>
        <population>Health-Related Quality of Life (HRQoL) Intent-to-Treat Analysis Dataset - comprised of all participants ≥12 years old who were randomized, had any available assessments at any available study visits (baseline, 6-month, and 12-month) as defined in the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Health-Related Quality of Life (HRQoL) - General Pain Assessment Using a Visual Analogue Scale (VAS) in Adults and Adolescents ≥12 Years Old</title>
          <description>General pain was assessed using a VAS pain scale at screening, 6 months, and at termination. Unlike the VAS pain assessment for pain of bleeding episodes (Outcome above), this general pain assessment did not take use of analgesics into account. For the pain scale, a higher number indicates worse pain.
The visual analog scale ranges from 0 to 100 where the endpoints are labeled 'Worst imaginable health state' (=0) and 'Best imaginable health state' (=100). A positive change from baseline indicates improvement.
Change in VAS scores at 6 months and study termination were also compared relative to Baseline/Screening scores (ie, (Baseline/Screening VAS score) - (VAS score at 6 months and study termination).</description>
          <population>Health-Related Quality of Life (HRQoL) Intent-to-Treat Analysis Dataset - comprised of all participants ≥12 years old who were randomized, had any available assessments at any available study visits (baseline, 6-month, and 12-month) as defined in the protocol</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening (N= 17, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.2" spread="30.15"/>
                    <measurement group_id="O2" value="55.5" spread="23.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (N= 16, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6" spread="25.81"/>
                    <measurement group_id="O2" value="32.7" spread="26.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Termination (N= 16, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" spread="21.97"/>
                    <measurement group_id="O2" value="29.8" spread="30.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change (Screening - Month 6) (N= 16, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="31.77"/>
                    <measurement group_id="O2" value="20.3" spread="38.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change (Screening - Termination) (N= 16, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="28.70"/>
                    <measurement group_id="O2" value="23.2" spread="46.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change (Month 6 - Termination) (N= 16, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="21.82"/>
                    <measurement group_id="O2" value="2.9" spread="19.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-Related Quality of Life (HRQoL) - General Pain Assessment Using a Visual Analogue Scale (VAS) in Pediatrics &lt;12 Years Old</title>
        <description>General pain was assessed using the children’s VAS pain scale (a facial expression scale with one end marked as no pain and the opposite end marked as the worst possible pain). Assessments were done at the screening, 6 months, and termination visits.
Scores on the children's VAS scale are presented as:
No Pain
Mild Pain
Moderate pain
Severe pain
Very severe pain
Unlike the VAS pain assessment for pain of bleeding episodes (Outcome above), this general pain assessment did not take use of analgesics into account.
Change in VAS scores at 6 months and study termination were also compared relative to Baseline/Screening scores (ie, (Baseline/Screening VAS score) - (VAS score at 6 months and study termination).</description>
        <time_frame>Baseline, 6 months and 12 months ± 14 days</time_frame>
        <population>Health-Related Quality of Life (HRQoL) Intent-to-Treat Analysis Dataset - comprised of all participants &lt;12 years old who were randomized, had any available assessments at any available study visits (baseline, 6-month, and 12-month) as defined in the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>On-demand Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis Arm</title>
            <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period</description>
          </group>
        </group_list>
        <measure>
          <title>Health-Related Quality of Life (HRQoL) - General Pain Assessment Using a Visual Analogue Scale (VAS) in Pediatrics &lt;12 Years Old</title>
          <description>General pain was assessed using the children’s VAS pain scale (a facial expression scale with one end marked as no pain and the opposite end marked as the worst possible pain). Assessments were done at the screening, 6 months, and termination visits.
Scores on the children's VAS scale are presented as:
No Pain
Mild Pain
Moderate pain
Severe pain
Very severe pain
Unlike the VAS pain assessment for pain of bleeding episodes (Outcome above), this general pain assessment did not take use of analgesics into account.
Change in VAS scores at 6 months and study termination were also compared relative to Baseline/Screening scores (ie, (Baseline/Screening VAS score) - (VAS score at 6 months and study termination).</description>
          <population>Health-Related Quality of Life (HRQoL) Intent-to-Treat Analysis Dataset - comprised of all participants &lt;12 years old who were randomized, had any available assessments at any available study visits (baseline, 6-month, and 12-month) as defined in the protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening - No Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening - Mild Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening - Moderate Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening - Severe Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Screening - Very Severe Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - No Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Mild Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Moderate Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Severe Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Very Severe Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Termination visit - No Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Termination visit - Mild Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Termination visit - Moderate Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Termination visit - Severe Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Termination visit - Very Severe Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study period of 3 years and 7 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>On-demand Arm</title>
          <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : Standard FEIBA NF dose and dosing interval as prescribed by the treating physician</description>
        </group>
        <group group_id="E2">
          <title>Prophylaxis Arm</title>
          <description>Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) : 85 ± 15 U/kg of FEIBA NF every other day during the 12-month ± 14 days prophylactic period</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Wall Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Haematoma Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatitis B Surface Antibody Positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="8" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Muscle Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Catheter Removal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Baxter's agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study: PIs may require prior written approval, or be restricted from independently publishing results until the earlier of the primary multicenter publication or ≤36 months after study completion. Baxter requires a review of results communications (e.g., for confidential information) prior to submission for publication, and shall review and if necessary amend the manuscript in ≤60 days</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wing-Yen Wong, MD, Global Sr Medical Dir Hemophilia</name_or_title>
      <organization>Baxter Healthcare Corporation</organization>
      <email>wing_yen_wong@baxter.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

